Document:

Exhibit
10.39 Form A

RESTRICTED STOCK
UNIT GRANT AGREEMENT

RESTRICTED STOCK
UNITS GRANTED UNDER THE

1998 IMS HEALTH INCORPORATED EMPLOYEES’ STOCK INCENTIVE PLAN

This Restricted
Stock Unit Grant Agreement, including the Terms and Conditions provided herewith
(together, the “Agreement”), confirms the grant of Restricted Stock Units (“RSUs”)
as of                       (the “Grant Date”) by the Compensation and
Benefits Committee (the “Committee”) of the Board of Directors of IMS Health
Incorporated (the “Company”) as follows:

	
  Participant Granted RSUs:

  	
                              

  
	
   

  	
   

  
	
  Number of RSUs
  Granted:

  	
                                             

  

 

The
RSUs are granted under the 1998 IMS Health Incorporated Employees’ Stock
Incentive Plan (the “Plan”).  The RSUs
are subject to all the terms and conditions of the Plan, which is provided
herewith and incorporated herein by reference, and are subject to the terms and
conditions of this Agreement.

The RSUs will vest
in four equal annual installments beginning on the first anniversary of the
Grant Date if Participant’s employment with the Company or a Subsidiary
continues through the vesting date, except as otherwise provided in the Plan
and this Agreement.

Participant
acknowledges and agrees that (i) until an RSU has become vested in accordance
with Section 2(a) hereof, such RSU will be subject to a risk of forfeiture to
the extent provided in such Section 2, and (ii) until the later of the time
each RSU becomes vested or the end of any additional period of deferral
permitted under applicable law and elected by Participant in accordance with
Section 4 hereof and such other rules and requirements of the Company as may be
established from time to time in the Committee’s sole discretion, such RSU
shall be generally nontransferable, as provided in Section 3 hereof.

IN WITNESS
WHEREOF, IMS Health Incorporated has caused this Agreement to be executed by
its officer thereunto duly authorized.

By
the Company’s signature, and Participant’s acceptance of these RSUs (as
described in the attached Terms and Conditions), the Company and Participant
agree to the terms of this Agreement.  If
Participant makes any deferral election with respect to the RSUs granted under
this Agreement, Participant must fill out a separate form or forms with respect
to such deferral election and return it to the Executive Compensation &
Equity Plans Department by the applicable deadline specified by the Company.

	
   

  	
  IMS HEALTH INCORPORATED

  
	
   

  	
   

  
	
   

  	
  David R.
  Carlucci

  
	
   

  	
  Chairman &
  Chief Executive Officer

  

 

TERMS AND
CONDITIONS

OF RESTRICTED STOCK UNITS

1.             Restricted Stock
Units

Each Restricted
Stock Unit (“RSU”) represents a generally nontransferable, conditional right to
receive one share of the Company’s Common Stock (a “Share”) at a specified
future date, together with a right to receive payments equivalent to dividends
paid on Shares (“Dividend Equivalents”) and other rights, subject to the terms
and conditions of the 1998 IMS Health Incorporated Employees’ Stock Incentive
Plan (the “Plan”) and this Agreement. 
RSUs are bookkeeping units, and do not represent ownership of Shares or
any other equity security.  The Company
shall maintain a bookkeeping account on behalf of Participant (the “Account”)
reflecting the number of RSUs then credited to Participant hereunder as a
result of this grant of RSUs and any crediting of additional RSUs to
Participant pursuant to payments of Dividend Equivalents under Section 5.  For purposes of this Agreement, the term RSUs
includes RSUs as to which the risk of forfeiture under Section 2 has lapsed but
which remain subject to Participant’s election to defer settlement.

2.             Vesting and
Forfeiture

(a)           RSUs granted hereunder
shall vest (meaning that the risk of forfeiture of such RSUs under this Section
2 shall lapse; such RSUs shall remain subject to Section 6) at the scheduled
lapse date set forth on the cover page of this Agreement, except that all RSUs
shall vest on an accelerated basis upon the earliest of (i) Termination of
Employment (as defined below) by reason of a Retirement, but only if the
Committee has specifically approved the accelerated vesting of the RSUs upon
such Retirement, (ii) Termination of Employment by reason of death or
Disability, (iii) upon the occurrence of a Change in Control, or (iv) any other
event specified as resulting in acceleration of RSUs in an employment agreement
between the Company and Participant in effect at the time of Termination of
Employment.  Each RSU credited as a
result of Dividend Equivalents on a forfeitable RSU and any cash amount payable
as Dividend Equivalents on a forfeitable RSU under Section 5(a) shall vest at
the time of vesting of the forfeitable RSU which gives rise, directly or
indirectly, to the crediting of such Dividend Equivalent RSU or cash.  Each RSU credited as a result of Dividend
Equivalents on a then non-forfeitable RSU under Section 5(a) shall be fully
vested and non-forfeitable from and after the date of such crediting, and any
cash amount credited as Dividend Equivalents on a then on-forfeitable RSU shall
be deemed to be fully vested and non-forfeitable at the time it is credited and
shall be paid at the time of settlement.

(b)           In the event of
Participant’s Termination of Employment, all RSUs that are not vested at or
prior to the time of such Termination shall be forfeited, unless otherwise
determined by the Committee.  Thus, upon
Participant’s voluntary Termination of Employment or a Termination of
Employment by the Company for Cause, unvested RSUs generally will be forfeited.

(c)           For purposes of this
Agreement, a Termination of Employment shall mean a termination of Participant’s
employment with the Company or a subsidiary or affiliate of the Company if,
immediately thereafter, Participant is not employed by any of the Company or
its subsidiaries or affiliates.

(d)           For purposes of this
Agreement, Cause shall have the meaning defined in an employment agreement
between the Company (or a subsidiary or affiliate) and

Participant in
effect at the time of Termination of Employment or, if there is no such
employment agreement, Cause shall mean (1) willful malfeasance or willful
misconduct by Participant in connection with his or her employment, (2)
continuing failure to perform such duties as are requested by any employee to
whom Participant reports, directly or indirectly, or by the board of directors
of either the Company or the subsidiary or affiliate that employs Participant,
(3) failure by Participant to observe policies of the Company or his or her
employer applicable to Participant, or (4) the commission by Participant of (i)
any felony or (ii) any misdemeanor involving moral turpitude.

3.             Nontransferability

Until the later of
the time each RSU becomes vested or the end of any additional period of
deferral elected by Participant in accordance with Section 4 below, such RSU
shall not be transferable or assignable other than by will or by the laws of
descent and distribution or to a designated Beneficiary in the event of
Participant’s death, and no such transfer shall be effective to bind the
Company unless the Committee shall have been furnished with a copy of such
will, Beneficiary designation, or such other evidence as the Committee may deem
necessary to establish the validity of the transfer.

4.             Settlement and
Election to Defer Settlement

RSUs granted
hereunder, together with RSUs credited as a result of Dividend Equivalents,
shall be settled by delivery of one Share for each RSU being settled.  Settlement of an RSU granted hereunder shall
occur upon the lapse of the risk of forfeiture of such RSU under Section 2,
except settlement shall be deferred if Participant has validly elected to defer
settlement in accordance with rules and requirements established by the Company
from time to time in its sole discretion and this Section 4.  Settlement of RSUs that directly or
indirectly result from Dividend Equivalents on RSUs granted hereunder shall
occur at the time of settlement of the granted RSU.

Deferrals, if
permitted, shall comply with requirements under Section 409A of the Internal
Revenue Code of 1986, as amended (the “Code”). 
Participant shall make elections relating to such deferral at times
meeting the requirements of Code Section 409A, using forms provided by the
Company (such forms are separate from this Agreement).  At any time that RSUs are treated as deferred
compensation subject to Code Section 409A, (i) they will be subject to
accelerated settlement under Section 10(b) of the Plan and Section 2(a) of this
Agreement only if the Change in Control constitutes a change in the ownership
or effective control of the Company, or in the ownership of a substantial
portion of the assets of the Company, within the meaning of Code Section
409A(a)(2)(A)(v), and (ii) settlement may not be accelerated in the discretion
of the Company (except to the extent permitted under Proposed Treasury
Regulation § 1.409A-3(h)(1) and (2)).  At
such time that RSUs are not treated as deferred compensation subject to Code
Section 409A and Participant has no further right to elect deferral in
conformity with Code Section 409A, RSUs shall be required to be settled
promptly upon the lapse of the risk of forfeiture, and in any event such
settlement must take place within 60 days after such lapse.  It is understood that Code Section 409A and
regulations thereunder may make it impractical for any such deferral to take
place.  Other provisions of this
Agreement notwithstanding, under U.S. federal income tax laws and Treasury
Regulations (including proposed regulations) as presently in effect or
hereafter implemented, (i) if the timing of any distribution in settlement of
RSUs would result in Participant’s constructive receipt of income relating to
the RSUs prior to such distribution, the date of distribution will be the
earliest date after the specified date of distribution that distribution can be
effected without resulting in such constructive receipt; (ii) in furtherance of
(i), any distribution the timing of which is tied to a termination of
employment will be made only at the time that the Participant has a

“separation from
service” within the meaning of Code Section 409A(a)(2)(A)(i), and any such
distribution shall occur not earlier until six months after separation from
service if the Participant is a “Specified Employee” within the meaning of Code
Section 409A(a)(2)(B)(i), if in either case the Participant otherwise would be
subject to constructive receipt of income relating to the RSUs prior to such
distribution; and (iii) any rights of Participant or retained authority of the
Company with respect to RSUs hereunder shall be automatically modified and
limited to the extent necessary so that Participant will not be deemed to be in
constructive receipt of income relating to the RSUs prior to the distribution
and so that Participant shall not be subject to any penalty under Section 409A.

Any elective
deferral will be subject to such additional terms and conditions as the
Committee may impose.  Please note
that, even if you elect to defer settlement, the Company is required to withhold
from you Medicare taxes at the applicable minimum statutory rate on the
scheduled lapse date for the deferred RSUs. 
Such withholding will be based upon the aggregate Fair Market Value of
the Shares underlying the deferred RSUs on the scheduled lapse date and will be
deducted from your salary normally in the payroll that immediately follows the
scheduled lapse date.

5.             Dividend
Equivalents and Adjustments

(a)           Dividend Equivalents
shall be paid or credited on RSUs (other than RSUs that, at the relevant record
date, previously have been settled or forfeited) as follows:

(i)                                     Cash Dividends.  If
the Company declares and pays a dividend or distribution on Common Stock in the
form of cash and the record date for such cash dividend is prior to the
settlement of the associated RSU, then a Participant shall be entitled to
Dividend Equivalents calculated at the time of such settlement and credited and
paid in cash at settlement, without interest.

(ii)                                  Non-Share Dividends. 
If the Company declares and pays a dividend or distribution on Common
Stock in the form of property other than Shares, then a number of additional
RSUs shall be credited to Participant’s Account as of the payment date for such
dividend or distribution equal to the number of RSUs credited to the Account as
of the record date for such dividend or distribution multiplied by the Fair
Market Value of such property actually paid as a dividend or distribution on
each outstanding Share at such payment date, divided by the Fair Market Value
of a Share at such payment date.

(iii)                               Common Stock Dividends and Splits.  If the Company declares and pays a dividend
or distribution on Common Stock in the form of additional Shares, or there
occurs a forward split of Common Stock, then a number of additional RSUs shall
be credited to Participant’s Account as of the payment date for such dividend
or distribution or forward split equal to the number of RSUs credited to the
Account as of the record date for such dividend or distribution or split
multiplied by the number of additional Shares actually paid as a dividend or
distribution or issued in such split in respect of each outstanding Share.

(b)           The number of RSUs
credited to Participant’s Account shall be appropriately adjusted, in order to
prevent dilution or enlargement of Participant’s rights with respect to RSUs,
to reflect any changes in the outstanding Shares resulting from any event
referred to in Section 10(a) of the Plan, taking into account any RSUs credited
to Participant in connection with such event under Section 5(a) hereof.

6.             Forfeiture of RSUs
and Shares Acquired Upon Prior Vesting and Settlement

The
greatest assets of IMS HEALTH, its subsidiaries and its affiliates (each, an “IMS
HEALTH Company”) are its employees, technology and customers.  In recognition of the increased risk of
unfairly losing any of these assets to its competitors, IMS HEALTH has adopted
the following policy:

If Participant
directly or indirectly engages in any of the “Detrimental Activities” defined
below:

(a)                                  any
unvested RSUs shall automatically be forfeited on the later of the date of
Participant’s Termination of Employment or the date IMS HEALTH becomes aware of
Participant’s Detrimental Activity, without regard to the provisions of Section
2; and

(b)                                 Participant
shall forfeit to the Company any RSUs that vested and the resulting Shares
acquired upon settlement during the one year prior to, or at any time after,
the date of the earliest actual occurrence of Participant’s Detrimental
Activity (the “Forfeiture Period”). 
These Shares shall be forfeited by Participant and are payable to the
Company at the later of the date of Participant’s Termination of Employment or
the date IMS HEALTH becomes aware of Participant’s Detrimental Activity.  If Participant has disposed of such Shares
during the Forfeiture Period, Participant’s obligation to repay Shares upon
such forfeiture will continue (payment of cash or other property is not
permitted), so that Participant will be required to acquire replacement Shares
and deliver them to the Company in settlement of Participant’s forfeiture
obligation without regard to any subsequent market price increase or decrease
from the date of exercise.  If
Participant fails to promptly deliver forfeited Shares and if, apart from this
Agreement, the Company is obligated to pay any cash amount to Participant, the
Company, as a setoff, may use such cash to purchase Shares in the open market
on Participant’s behalf, which Shares will be retained by the Company in
settlement of Participant’s forfeiture obligation hereunder.

Detrimental Activities
are defined as:

·                  using or disclosing any information that has
been treated by an IMS HEALTH Company as confidential or proprietary and is of
competitive advantage to such IMS HEALTH Company, unless Participant is using or disclosing it in the course of Participant’s job with such IMS HEALTH Company;

·                  during
the period beginning the Date of Grant and ending twelve months after
Participant leaves his or her employment with any IMS HEALTH Company (the “Prohibited
Period”), soliciting, inducing, enticing or procuring for anyone other than an
IMS HEALTH Company the trade or business of any entity that was a customer
(including “near-permanent” customers), prospective customer or data supplier
of an IMS HEALTH Company, in order to sell to such customer or prospective
customer, or obtain from such data supplier, the same, similar or related
services IMS HEALTH offers to its customers, or such data supplier provided to
IMS HEALTH, during the period that Participant worked for any IMS HEALTH
Company;

·                  during
the Prohibited Period, soliciting, inducing, enticing or procuring any employee
of any IMS HEALTH Company to leave his or her employment; or employing or
otherwise using the services of any person who is or was an IMS HEALTH Company
employee during the last twelve months that Participant worked for an IMS
HEALTH Company; or

·                  during
the Prohibited Period, directly or indirectly (including without limitation as
an

officer, director,
employee, advisor, agent, consultant or investor, other than by the ownership
of a passive investment interest of not more than 1% in a company with publicly
traded equity securities), (i) seeking or accepting any employment or other
work with or providing assistance to any person or entity that offers
Competitive Services (as defined below) to any person or entity that was a
customer or potential customer of any IMS HEALTH Company at any time during the
last two years of Participant’s employment with any IMS HEALTH Company, or (ii)
otherwise providing Competitive Services.

For
purposes hereof, “Competitive Services” means engaging in the following
activities anywhere in the world in relation to the pharmaceutical and
healthcare industries (it being understood that the global market in which any
of the businesses of IMS is conducted and to which their goodwill extends is
not limited to any particular region in the world and that given the
informational nature of such businesses, they may be engaged effectively from
any location in the world):

·                  providing
information services for the management of sales forces engaged in the sale of
prescription or over-the-counter drugs, medical devices, or medical or surgical
products;

·                  providing
information services for the measurement of sales force performance or product
performance for prescription or over-the-counter drugs, medical devices, or
medical or surgical products;

·                  creating
or providing physician profiles for purposes of assisting others in the
targeting of promotion or sales activities in relation to prescription or
over-the-counter drugs, medical devices, or medical or surgical products;

·                  creating
or providing micromarketing programs based on prescribing behavior or attitudes
of physicians or other prescribers in relation to prescription or over-the-counter
drugs, medical devices, or medical or surgical products;

·                  creating
or providing market research reports or audits relating to the use, sale,
marketing/promotion, distribution or warehousing of any prescription or
over-the-counter drugs, medical devices, or medical or surgical products;

·                  using
or developing technology, methodologies or processes which have functionality
or produce results similar to the technology, methodologies or processes
employed or offered by IMS HEALTH to process pharmaceutical or healthcare
information, including but not limited to internal processing technology,
decision support tools, data warehousing applications and data mining
applications;

·                  creating
or providing reference files, classification schemes, master files or other
methods of categorizing, classifying, organizing or identifying products,
procedures, medical facilities, pharmacies, warehouses, distributors,
prescribers, pharmacists or other entities, activities or persons associated
with the use, sale, marketing/promotion, distribution or warehousing of any
prescription or over-the-counter drugs, medical devices, or medical or surgical
products; or

·                  providing
market research consulting, sales management consulting, information technology
consulting or market event management consulting, or any other consulting
services in connection with any of the foregoing activities or otherwise
relating to the use, sale, marketing/promotion, distribution or warehousing of
any prescription or over-the-counter drugs, medical devices, or medical or
surgical

products.

7.             Other Terms
Relating to RSUs

(a)           The number of RSUs
credited to a Participant’s Account shall include fractional RSUs calculated to
at least three decimal places, unless otherwise determined by the
Committee.  Upon settlement of RSUs,
Participant shall be paid, in cash, an amount equal to the value of any
fractional share that would have otherwise been deliverable in settlement of
such RSUs, unless the Company arranges to deliver shares to an account of
Participant to which fractional shares may be credited without requiring the
Company to in fact issue a fractional share.

(b)           It shall be a condition
to the obligation of the Company to issue and deliver Shares in settlement of
the RSUs that Participant (or any Beneficiary) pay to the Company (or a
subsidiary or affiliate), upon its demand, such amount as may be requested by
the Company for the purpose of satisfying the minimum statutory withholding
liabilities for federal, state, or local income or other taxes.  If the amount requested is not paid, the
Company may refuse to deliver the Shares in settlement of the RSUs until such
amount is paid.  Unless otherwise
determined by the Committee or unless Participant (or a Beneficiary) has prior
to the settlement date made alternative arrangements satisfactory to the
Company to pay withholding taxes applicable upon settlement, the Company shall
withhold from the Shares to be delivered in settlement of the RSUs that number
of Shares having a fair market value equal to the amount of such tax liability
(or as nearly equal as possible without exceeding the amount of such tax
liability).  For this purpose, the fair
market value of the withheld Shares shall be the average high/low sales prices
in composite trading of New York Stock Exchange Listed securities on the day on
which the Shares are withheld.  Shares
will not be withheld by the Company to satisfy withholding taxes (i.e., FICA)
due upon the lapse of the risk of forfeiture if settlement of the RSUs is
deferred for a period of time thereafter.

8.             Miscellaneous

(a)           This Agreement shall be
legally binding when executed by the Company and accepted by Participant as
described below, provided that no election of Participant will be binding
unless Participant has accepted the Agreement and the terms of the Plan (as
described below).

(b)           This Agreement shall be
binding upon the heirs, executors, administrators and successors of the
parties.  This Agreement constitutes the
entire agreement between the parties with respect to the RSUs, and supersedes
any prior agreements or documents with respect to the RSUs.  No amendment, alteration, suspension,
discontinuation or termination of this Agreement which may impose any
additional obligation upon the Company or impair the rights of Participant with
respect to the RSUs shall be valid unless in each instance such amendment,
alteration, suspension, discontinuation or termination is expressed in a
written instrument duly executed (or accepted electronically, if permitted in
the sole discretion of the Committee) in the name and on behalf of the Company
and by Participant.

(c)           Any Beneficiary
designation made by Participant in accordance with this provision may be
changed from time to time, without the consent of any previously designated
Beneficiary (but subject to any spousal consent as may be required) by filing
with the Executive Compensation & Equity Plans Department a notice of such
change.   The

change of
Beneficiary designation shall become effective upon receipt by the Executive
Compensation & Equity Plans Department. 
In the event Participant’s Beneficiary would otherwise become entitled
to a distribution hereunder, and all Beneficiaries designated by Participant
are not then living, or if no valid Beneficiary designation is in effect, Participant’s
estate or duly authorized personal representative shall be deemed to have been
designated by Participant.

(d)           Any provision for
distribution in settlement of Participant’s Account hereunder shall be by means
of bookkeeping entries on the books of the Company and shall not create in
Participant or any Beneficiary any right to, or claim against any, specific
assets of the Company, nor result in the creation of any trust or escrow
account for Participant or any Beneficiary. 
Participant or any Beneficiary entitled to any distribution hereunder
shall be a general creditor of the Company.

(e)           Participant agrees and
acknowledges that the Plan is discretionary in nature and the Company may
amend, cancel or terminate the Plan at any time.  The grant of RSUs is a one-time benefit
solely offered to employees and does not create any contractual or other right
to receive a grant of RSUs or benefits in lieu of RSUs in the future.  Future grants, if any, will be at the sole discretion
of the Company, including, but not limited to, the timing of any grant, the
number of RSUs and vesting provisions.

(f)            Participant agrees and
acknowledges that his or her participation in the Plan and his or her execution
of this Agreement is voluntary.  The
value of equity incentive awards generally and Participant’s RSUs specifically
is an extraordinary item of compensation outside the scope of Participant’s
employment contract, if any, and does not constitute compensation of any kind
for services of any kind rendered to the Company (or any of its subsidiaries or
affiliates).  As such, neither equity
incentive awards generally nor Participant’s RSUs specifically are part of
normal or expected compensation for purposes of calculating any termination,
severance, resignation, redundancy, end of service payments, bonuses, long
service awards, pension or retirement benefits, or similar payments.

(g)           Participant
acknowledges and agrees that he or she will have no claim or entitlement (1) to
compensation or damages in consequence of the Termination of Employment with
the Company (or any of its subsidiaries or affiliates) for any reason
whatsoever and whether or not in breach of contract, insofar as such claim or
entitlement arises or may arise from Participant ceasing to have any rights
under the Plan or this Agreement, (2) to vest in his or her RSUs as a result of
such Termination of Employment except as expressly provided in this Agreement,
or (3) from the loss or diminution in value of his or her RSUs; and, upon the
grant of Participant’s RSUs and in partial consideration for his or her
participation in the Plan and this Agreement, Participant shall be deemed
irrevocably to have waived any such claim or entitlement.

(h)           Participant voluntarily
acknowledges and consents to the collection, use, processing and transfer of
personal data as described in this paragraph. 
Participant is not obliged to consent to such collection, use,
processing and transfer of personal data. 
However, failure to provide the consent may affect Participant’s ability
to participate in the Plan.  The Company,
its subsidiaries and its affiliates hold certain personal information about
Participant, including Participant’s name, home address and telephone number,
date of birth, social insurance number or other employee identification number,
salary, nationality, job title, any shares of stock or directorships held in
the Company, details of Participant’s RSUs, all other equity incentive awards
or any other rights or entitlements to Shares in your favor, for the purpose of
managing and administering the Plan (“Data”). 
The Company, its subsidiaries and/or its affiliates will transfer Data
amongst themselves as necessary for the purpose of implementation, administration
and management of

Participant’s
participation in the Plan, and the Company, its subsidiaries and/or its
affiliates may each further transfer Data to any third parties assisting the
Company in the implementation, administration and management of the Plan.  These recipients may be located in the
European Economic Area, or elsewhere throughout the world, such as the United
States.  Participant authorizes them to
receive, possess, use, retain and transfer the Data, in electronic or other
form, for the purposes of implementing, administering and managing his or her
participation in the Plan, including any requisite transfer of such Data as may
be required for the administration of the Plan and/or the subsequent holding of
Shares on Participant’s behalf to a broker or other third party with whom
Participant may elect to deposit any Shares acquired pursuant to the Plan.  Participant may, at any time, review Data,
require any necessary amendments to it or withdraw the consents herein in
writing by contacting the Company; however, withdrawing his or her consent may
affect Participant’s ability to participate in the Plan.  Participant acknowledges and agrees that his
or her consent shall apply to any and all restricted stock unit awards made to
him or her under the Plan or this Agreement, whether now or in the future.

(i)            Capitalized terms used
in this Agreement but not defined herein shall have the same meanings as in the
Plan.  If there is any conflict between
the provisions of this Agreement and the provisions of the Plan, the provisions
of the Plan shall govern, except as otherwise specifically provided herein.

(j)            THE PLAN AND THIS
AGREEMENT SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK AND ANY
APPLICABLE FEDERAL LAWS.  INTERPRETATION
OF THE PLAN AND THIS AGREEMENT SHALL BE GOVERNED BY THE LAWS OF THE STATE OF
NEW YORK AND ANY APPLICABLE FEDERAL LAWS. 
ANY LEGAL PROCEEDING ARISING OUT OF THE PLAN OR THIS AGREEMENT SHALL BE
BROUGHT EXCLUSIVELY IN THE FEDERAL OR STATE COURTS LOCATED IN THE STATE OF NEW
YORK.  YOU AGREE TO SUBMIT TO PERSONAL
JURISDICTION AND TO VENUE IN THOSE COURTS. 
YOU FURTHER AGREE TO WAIVE ALL LEGAL CHALLENGES AND DEFENSES TO THE
APPROPRIATENESS OF NEW YORK AS THE SITE OF ANY SUCH LEGAL PROCEEDING AND TO THE
APPLICATION OF THE LAWS OF THE STATE OF NEW YORK AND ANY APPLICABLE FEDERAL
LAWS.

*  * 
*  *  *

You
do not need to do anything if you want to accept your RSUs on the terms set out
in this Agreement.  If you do not want to
accept your RSUs on the terms set out in this Agreement, please write to the
Company at the address below, marking your envelope to the attention of Kristin
Johnson, no later than
                              .

IMS Health

Executive Compensation & Equity Plans

660 W. Germantown Pike

Plymouth Meeting, Pennsylvania 19462

U.S.A

Your RSUs will
then be cancelled.  If you do not write
to us telling us that you do no want you RSUs by                               ,
you will have accepted your RSUs and agreed to the terms set out in this
Agreement.

IMS
HEALTH INCORPORATED

David R. Carlucci

Chairman &
Chief Executive Officer

Exhibit
10.39 Form B

RESTRICTED STOCK
UNIT GRANT AGREEMENT

RESTRICTED STOCK
UNITS GRANTED UNDER THE

1998 IMS HEALTH INCORPORATED EMPLOYEES’ STOCK INCENTIVE PLAN

This Restricted
Stock Unit Grant Agreement, including the Terms and Conditions provided herewith
(together, the “Agreement”), confirms the grant of Restricted Stock Units (“RSUs”)
as of                                     
(the “Grant Date”) by the Compensation and Benefits Committee (the “Committee”)
of the Board of Directors of IMS Health Incorporated (the “Company”) as
follows:

	
  Participant Granted RSUs:

  	
   

  
	
   

  	
   

  
	
  Number of RSUs
  Granted:

  	
   

  

 

The
RSUs are granted under the 1998 IMS Health Incorporated Employees’ Stock
Incentive Plan (the “Plan”).  The RSUs are
subject to all the terms and conditions of the Plan, which is provided herewith
and incorporated herein by reference, and are subject to the terms and
conditions of this Agreement.

The RSUs will vest
in four equal annual installments beginning on the first anniversary of the
Grant Date if Participant’s employment with the Company or a Subsidiary
continues through the vesting date, except as otherwise provided in the Plan
and this Agreement..

Participant
acknowledges and agrees that (i) until an RSU has become vested in accordance
with Section 2(a) hereof, such RSU will be subject to a risk of forfeiture to
the extent provided in such Section 2, and (ii) until the later of the time
each RSU becomes vested or the end of any additional period of deferral permitted
under applicable law and elected by Participant in accordance with Section 4
hereof and such other rules and requirements of the Company as may be
established from time to time in the Committee’s sole discretion, such RSU
shall be generally nontransferable, as provided in Section 3 hereof.

IN WITNESS
WHEREOF, IMS Health Incorporated has caused this Agreement to be executed by
its officer thereunto duly authorized.

By
the Company’s signature, and Participant’s acceptance of these RSUs (as
described in the attached Terms and Conditions), the Company and Participant
agree to the terms of this Agreement.  If
Participant makes any deferral election with respect to the RSUs granted under
this Agreement, Participant must fill out a separate form or forms with respect
to such deferral election and return it to the Executive Compensation &
Equity Plans Department by the applicable deadline specified by the Company.

	
   

  	
  IMS HEALTH INCORPORATED

  
	
   

  	
   

  
	
   

  	
  David R.
  Carlucci

  
	
   

  	
  Chairman &
  Chief Executive Officer

  

TERMS AND
CONDITIONS

OF RESTRICTED STOCK UNITS

1.             Restricted Stock Units

Each Restricted
Stock Unit (“RSU”) represents a generally nontransferable, conditional right to
receive one share of the Company’s Common Stock (a “Share”) at a specified
future date, together with a right to receive payments equivalent to dividends
paid on Shares (“Dividend Equivalents”) and other rights, subject to the terms
and conditions of the 1998 IMS Health Incorporated Employees’ Stock Incentive
Plan (the “Plan”) and this Agreement. 
RSUs are bookkeeping units, and do not represent ownership of Shares or
any other equity security.  The Company
shall maintain a bookkeeping account on behalf of Participant (the “Account”)
reflecting the number of RSUs then credited to Participant hereunder as a
result of this grant of RSUs and any crediting of additional RSUs to
Participant pursuant to payments of Dividend Equivalents under Section 5.  For purposes of this Agreement, the term RSUs
includes RSUs as to which the risk of forfeiture under Section 2 has lapsed but
which remain subject to Participant’s election to defer settlement.

2.             Vesting and Forfeiture

(a)           RSUs granted hereunder shall vest
(meaning that the risk of forfeiture of such RSUs under this Section 2 shall lapse;
such RSUs shall remain subject to Section 6) at the scheduled lapse date set
forth on the cover page of this Agreement, except that all RSUs shall vest on
an accelerated basis upon Termination of Employment by reason of death or
Disability.  Each RSU credited as a
result of Dividend Equivalents on a forfeitable RSU and any cash amount payable
as Dividend Equivalents on a forfeitable RSU under Section 5(a) shall vest at
the time of vesting of the forfeitable RSU which gives rise, directly or
indirectly, to the crediting of such Dividend Equivalent RSU or cash.  Each RSU credited as a result of Dividend
Equivalents on a then non-forfeitable RSU under Section 5(a) shall be fully
vested and non-forfeitable from and after the date of such crediting, and any cash
amount credited as Dividend Equivalents on a then on-forfeitable RSU shall be
deemed to be fully vested and non-forfeitable at the time it is credited and
shall be paid at the time of settlement.

(b)           In the event of Participant’s
Termination of Employment, all RSUs that are not vested at or prior to the time
of such Termination shall be forfeited, unless otherwise determined by the
Committee.  Thus, upon Participant’s
voluntary Termination of Employment or a Termination of Employment by the
Company for Cause, unvested RSUs generally will be forfeited.

(c)           For purposes of this Agreement, a
Termination of Employment shall mean a termination of Participant’s employment
with the Company or a subsidiary or affiliate of the Company if, immediately
thereafter, Participant is not employed by any of the Company or its
subsidiaries or affiliates.

(d)           For purposes of this Agreement, Cause
shall have the meaning defined in an employment agreement between the Company
(or a subsidiary or affiliate) and Participant in effect at the time of
Termination of Employment or, if there is no such employment agreement, Cause
shall mean (1) willful malfeasance or willful misconduct by Participant in
connection with his or her employment, (2) continuing failure to perform such duties
as are requested by any employee to whom Participant reports, directly or
indirectly, or by the board of directors of either the Company or the
subsidiary or affiliate that employs Participant, (3) failure by Participant to
observe policies of the Company or his or her

employer
applicable to Participant, or (4) the commission by Participant of (i) any
felony or (ii) any misdemeanor involving moral turpitude.

3.             Nontransferability

Until the later of
the time each RSU becomes vested or the end of any additional period of
deferral elected by Participant in accordance with Section 4 below, such RSU
shall not be transferable or assignable other than by will or by the laws of
descent and distribution or to a designated Beneficiary in the event of
Participant’s death, and no such transfer shall be effective to bind the
Company unless the Committee shall have been furnished with a copy of such
will, Beneficiary designation, or such other evidence as the Committee may deem
necessary to establish the validity of the transfer.

4.             Settlement and Election to Defer
Settlement

RSUs granted
hereunder, together with RSUs credited as a result of Dividend Equivalents,
shall be settled by delivery of one Share for each RSU being settled.  Settlement of an RSU granted hereunder shall
occur upon the lapse of the risk of forfeiture of such RSU under Section 2,
except settlement shall be deferred if Participant has validly elected to defer
settlement in accordance with rules and requirements established by the Company
from time to time in its sole discretion and this Section 4.  Settlement of RSUs that directly or
indirectly result from Dividend Equivalents on RSUs granted hereunder shall
occur at the time of settlement of the granted RSU.

Deferrals, if
permitted, shall comply with requirements under Section 409A of the Internal
Revenue Code of 1986, as amended (the “Code”). 
Participant shall make elections relating to such deferral at times
meeting the requirements of Code Section 409A, using forms provided by the
Company (such forms are separate from this Agreement).  At any time that RSUs are treated as deferred
compensation subject to Code Section 409A, (i) they will be subject to
accelerated settlement under Section 10(b) of the Plan and Section 2(a) of this
Agreement only if the Change in Control constitutes a change in the ownership
or effective control of the Company, or in the ownership of a substantial
portion of the assets of the Company, within the meaning of Code Section
409A(a)(2)(A)(v), and (ii) settlement may not be accelerated in the discretion
of the Company (except to the extent permitted under Proposed Treasury
Regulation § 1.409A-3(h)(1) and (2)).  At
such time that RSUs are not treated as deferred compensation subject to Code
Section 409A and Participant has no further right to elect deferral in
conformity with Code Section 409A, RSUs shall be required to be settled
promptly upon the lapse of the risk of forfeiture, and in any event such
settlement must take place within 60 days after such lapse.  It is understood that Code Section 409A and
regulations thereunder may make it impractical for any such deferral to take
place.  Other provisions of this
Agreement notwithstanding, under U.S. federal income tax laws and Treasury Regulations
(including proposed regulations) as presently in effect or hereafter
implemented, (i) if the timing of any distribution in settlement of RSUs would
result in Participant’s constructive receipt of income relating to the RSUs
prior to such distribution, the date of distribution will be the earliest date
after the specified date of distribution that distribution can be effected
without resulting in such constructive receipt; (ii) in furtherance of (i), any
distribution the timing of which is tied to a termination of employment will be
made only at the time that the Participant has a “separation from service”
within the meaning of Code Section 409A(a)(2)(A)(i), and any such distribution
shall occur not earlier until six months after separation from service if the
Participant is a “Specified Employee” within the meaning of Code Section
409A(a)(2)(B)(i), if in either case the Participant otherwise would be subject
to constructive receipt of income relating to the RSUs prior to such
distribution; and (iii) any rights of Participant or retained authority of the
Company with respect to RSUs hereunder shall be automatically modified

and limited to the
extent necessary so that Participant will not be deemed to be in constructive
receipt of income relating to the RSUs prior to the distribution and so that
Participant shall not be subject to any penalty under Section 409A.

Any elective
deferral will be subject to such additional terms and conditions as the
Committee may impose.  Please note
that, even if you elect to defer settlement, the Company is required to
withhold from you Medicare taxes at the applicable minimum statutory rate on
the scheduled lapse date for the deferred RSUs.  Such withholding will be based upon the
aggregate Fair Market Value of the Shares underlying the deferred RSUs on the
scheduled lapse date and will be deducted from your salary normally in the
payroll that immediately follows the scheduled lapse date.

5.             Dividend Equivalents and
Adjustments

(a)           Dividend Equivalents shall be paid or
credited on RSUs (other than RSUs that, at the relevant record date, previously
have been settled or forfeited) as follows:

(i)                                     Cash Dividends.  If
the Company declares and pays a dividend or distribution on Common Stock in the
form of cash and the record date for such cash dividend is prior to the
settlement of the associated RSU, then a Participant shall be entitled to
Dividend Equivalents calculated at the time of such settlement and credited and
paid in cash at settlement, without interest.

(ii)                                  Non-Share Dividends. 
If the Company declares and pays a dividend or distribution on Common
Stock in the form of property other than Shares, then a number of additional
RSUs shall be credited to Participant’s Account as of the payment date for such
dividend or distribution equal to the number of RSUs credited to the Account as
of the record date for such dividend or distribution multiplied by the Fair
Market Value of such property actually paid as a dividend or distribution on
each outstanding Share at such payment date, divided by the Fair Market Value of
a Share at such payment date.

(iii)                               Common Stock Dividends and Splits.  If the Company declares and pays a dividend
or distribution on Common Stock in the form of additional Shares, or there
occurs a forward split of Common Stock, then a number of additional RSUs shall
be credited to Participant’s Account as of the payment date for such dividend
or distribution or forward split equal to the number of RSUs credited to the
Account as of the record date for such dividend or distribution or split
multiplied by the number of additional Shares actually paid as a dividend or
distribution or issued in such split in respect of each outstanding Share.

(b)           The number of RSUs credited to
Participant’s Account shall be appropriately adjusted, in order to prevent
dilution or enlargement of Participant’s rights with respect to RSUs, to
reflect any changes in the outstanding Shares resulting from any event referred
to in Section 10(a) of the Plan, taking into account any RSUs credited to
Participant in connection with such event under Section 5(a) hereof.

6.             Forfeiture of RSUs and Shares
Acquired Upon Prior Vesting and Settlement

The
greatest assets of IMS HEALTH, its subsidiaries and its affiliates (each, an “IMS
HEALTH Company”) are its employees, technology and customers.  In recognition of the increased risk of
unfairly losing any of these assets to its competitors, IMS HEALTH has adopted
the following policy:

If Participant
directly or indirectly engages in any of the “Detrimental Activities” defined
below:

(a)                                  any
unvested RSUs shall automatically be forfeited on the later of the date of
Participant’s Termination of Employment or the date IMS HEALTH becomes aware of
Participant’s Detrimental Activity, without regard to the provisions of Section
2; and

(b)                                 Participant
shall forfeit to the Company any RSUs that vested and the resulting Shares
acquired upon settlement during the one year prior to, or at any time after,
the date of the earliest actual occurrence of Participant’s Detrimental
Activity (the “Forfeiture Period”). 
These Shares shall be forfeited by Participant and are payable to the
Company at the later of the date of Participant’s Termination of Employment or
the date IMS HEALTH becomes aware of Participant’s Detrimental Activity.  If Participant has disposed of such Shares
during the Forfeiture Period, Participant’s obligation to repay Shares upon
such forfeiture will continue (payment of cash or other property is not
permitted), so that Participant will be required to acquire replacement Shares
and deliver them to the Company in settlement of Participant’s forfeiture
obligation without regard to any subsequent market price increase or decrease
from the date of exercise.  If
Participant fails to promptly deliver forfeited Shares and if, apart from this
Agreement, the Company is obligated to pay any cash amount to Participant, the
Company, as a setoff, may use such cash to purchase Shares in the open market
on Participant’s behalf, which Shares will be retained by the Company in
settlement of Participant’s forfeiture obligation hereunder.

Detrimental Activities
are defined as:

·                  using or disclosing any information that has
been treated by an IMS HEALTH Company as confidential or proprietary and is of
competitive advantage to such IMS HEALTH Company, unless Participant is using or disclosing it in the course of Participant’s job with such IMS HEALTH Company;

·                  during
the period beginning the Date of Grant and ending twelve months after
Participant leaves his or her employment with any IMS HEALTH Company (the “Prohibited
Period”), soliciting, inducing, enticing or procuring for anyone other than an
IMS HEALTH Company the trade or business of any entity that was a customer
(including “near-permanent” customers), prospective customer or data supplier
of an IMS HEALTH Company, in order to sell to such customer or prospective
customer, or obtain from such data supplier, the same, similar or related
services IMS HEALTH offers to its customers, or such data supplier provided to
IMS HEALTH, during the period that Participant worked for any IMS HEALTH
Company;

·                  during
the Prohibited Period, soliciting, inducing, enticing or procuring any employee
of any IMS HEALTH Company to leave his or her employment; or employing or
otherwise using the services of any person who is or was an IMS HEALTH Company
employee during the last twelve months that Participant worked for an IMS
HEALTH Company; or

·                  during
the Prohibited Period, directly or indirectly (including without limitation as
an officer, director, employee, advisor, agent, consultant or investor, other
than by the ownership of a passive investment interest of not more than 1% in a
company with publicly traded equity securities), (i) seeking or accepting any
employment or other work with or providing assistance to any person or entity
that offers Competitive Services (as defined below) to any person or entity
that was a customer or potential customer of any IMS HEALTH Company at any time
during the last two years of

Participant’s
employment with any IMS HEALTH Company, or (ii) otherwise providing Competitive
Services.

For
purposes hereof, “Competitive Services” means engaging in the following
activities anywhere in the world in relation to the pharmaceutical and
healthcare industries (it being understood that the global market in which any
of the businesses of IMS is conducted and to which their goodwill extends is
not limited to any particular region in the world and that given the
informational nature of such businesses, they may be engaged effectively from
any location in the world):

·                  providing
information services for the management of sales forces engaged in the sale of
prescription or over-the-counter drugs, medical devices, or medical or surgical
products;

·                  providing
information services for the measurement of sales force performance or product
performance for prescription or over-the-counter drugs, medical devices, or
medical or surgical products;

·                  creating
or providing physician profiles for purposes of assisting others in the
targeting of promotion or sales activities in relation to prescription or
over-the-counter drugs, medical devices, or medical or surgical products;

·                  creating
or providing micromarketing programs based on prescribing behavior or attitudes
of physicians or other prescribers in relation to prescription or
over-the-counter drugs, medical devices, or medical or surgical products;

·                  creating
or providing market research reports or audits relating to the use, sale,
marketing/promotion, distribution or warehousing of any prescription or
over-the-counter drugs, medical devices, or medical or surgical products;

·                  using
or developing technology, methodologies or processes which have functionality
or produce results similar to the technology, methodologies or processes
employed or offered by IMS HEALTH to process pharmaceutical or healthcare
information, including but not limited to internal processing technology,
decision support tools, data warehousing applications and data mining
applications;

·                  creating
or providing reference files, classification schemes, master files or other
methods of categorizing, classifying, organizing or identifying products,
procedures, medical facilities, pharmacies, warehouses, distributors,
prescribers, pharmacists or other entities, activities or persons associated
with the use, sale, marketing/promotion, distribution or warehousing of any
prescription or over-the-counter drugs, medical devices, or medical or surgical
products; or

·                  providing
market research consulting, sales management consulting, information technology
consulting or market event management consulting, or any other consulting
services in connection with any of the foregoing activities or otherwise
relating to the use, sale, marketing/promotion, distribution or warehousing of
any prescription or over-the-counter drugs, medical devices, or medical or
surgical products.

7.             Other
Terms Relating to RSUs

(a)           The number of RSUs credited to a
Participant’s Account shall include fractional RSUs calculated to at least
three decimal places, unless otherwise determined by

the Committee.  Upon settlement of RSUs, Participant shall be
paid, in cash, an amount equal to the value of any fractional share that would
have otherwise been deliverable in settlement of such RSUs, unless the Company
arranges to deliver shares to an account of Participant to which fractional
shares may be credited without requiring the Company to in fact issue a
fractional share.

(b)           It shall be a condition to the
obligation of the Company to issue and deliver Shares in settlement of the RSUs
that Participant (or any Beneficiary) pay to the Company (or a subsidiary or
affiliate), upon its demand, such amount as may be requested by the Company for
the purpose of satisfying the minimum statutory withholding liabilities for
federal, state, or local income or other taxes. 
If the amount requested is not paid, the Company may refuse to deliver
the Shares in settlement of the RSUs until such amount is paid.  Unless otherwise determined by the Committee
or unless Participant (or a Beneficiary) has prior to the settlement date made
alternative arrangements satisfactory to the Company to pay withholding taxes
applicable upon settlement, the Company shall withhold from the Shares to be
delivered in settlement of the RSUs that number of Shares having a fair market
value equal to the amount of such tax liability (or as nearly equal as possible
without exceeding the amount of such tax liability).  For this purpose, the fair market value of
the withheld Shares shall be the average high/low sales prices in composite
trading of New York Stock Exchange Listed securities on the day on which the
Shares are withheld.  Shares will not be
withheld by the Company to satisfy withholding taxes (i.e., FICA) due upon the
lapse of the risk of forfeiture if settlement of the RSUs is deferred for a
period of time thereafter.

8.             Miscellaneous

(a)           This Agreement shall be legally
binding when executed by the Company and accepted by Participant as described
below, provided that no election of Participant will be binding unless
Participant has accepted the Agreement and the terms of the Plan (as described
below).

(b)           This Agreement shall be binding upon
the heirs, executors, administrators and successors of the parties.  This Agreement constitutes the entire
agreement between the parties with respect to the RSUs, and supersedes any
prior agreements or documents with respect to the RSUs.  No amendment, alteration, suspension,
discontinuation or termination of this Agreement which may impose any
additional obligation upon the Company or impair the rights of Participant with
respect to the RSUs shall be valid unless in each instance such amendment,
alteration, suspension, discontinuation or termination is expressed in a
written instrument duly executed (or accepted electronically, if permitted in
the sole discretion of the Committee) in the name and on behalf of the Company
and by Participant.

(c)           Any Beneficiary designation made by
Participant in accordance with this provision may be changed from time to time,
without the consent of any previously designated Beneficiary (but subject to
any spousal consent as may be required) by filing with the Executive
Compensation & Equity Plans Department a notice of such change.   The change of Beneficiary designation shall
become effective upon receipt by the Executive Compensation & Equity Plans
Department.  In the event Participant’s
Beneficiary would otherwise become entitled to a distribution hereunder, and
all Beneficiaries designated by Participant are not then living, or if no valid
Beneficiary designation is in effect, Participant’s estate or duly authorized
personal representative shall be deemed to have been designated by Participant.

(d)           Any provision for distribution in
settlement of Participant’s Account hereunder shall be by means of bookkeeping
entries on the books of the Company and shall not create in Participant or any
Beneficiary any right to, or claim against any, specific assets of the Company,
nor result in the creation of any trust or escrow account for Participant or
any Beneficiary.  Participant or any
Beneficiary entitled to any distribution hereunder shall be a general creditor
of the Company.

(e)           Participant agrees and acknowledges
that the Plan is discretionary in nature and the Company may amend, cancel or
terminate the Plan at any time.  The grant
of RSUs is a one-time benefit solely offered to employees and does not create
any contractual or other right to receive a grant of RSUs or benefits in lieu
of RSUs in the future.  Future grants, if
any, will be at the sole discretion of the Company, including, but not limited
to, the timing of any grant, the number of RSUs and vesting provisions.

(f)            Participant agrees and acknowledges
that his or her participation in the Plan and his or her execution of this
Agreement is voluntary.  The value of
equity incentive awards generally and Participant’s RSUs specifically is an
extraordinary item of compensation outside the scope of Participant’s
employment contract, if any, and does not constitute compensation of any kind
for services of any kind rendered to the Company (or any of its subsidiaries or
affiliates).  As such, neither equity
incentive awards generally nor Participant’s RSUs specifically are part of
normal or expected compensation for purposes of calculating any termination,
severance, resignation, redundancy, end of service payments, bonuses, long
service awards, pension or retirement benefits, or similar payments.

(g)           Participant acknowledges and agrees
that he or she will have no claim or entitlement (1) to compensation or damages
in consequence of the Termination of Employment with the Company (or any of its
subsidiaries or affiliates) for any reason whatsoever and whether or not in
breach of contract, insofar as such claim or entitlement arises or may arise
from Participant ceasing to have any rights under the Plan or this Agreement,
(2) to vest in his or her RSUs as a result of such Termination of Employment
except as expressly provided in this Agreement, or (3) from the loss or
diminution in value of his or her RSUs; and, upon the grant of Participant’s
RSUs and in partial consideration for his or her participation in the Plan and
this Agreement, Participant shall be deemed irrevocably to have waived any such
claim or entitlement.

(h)           Participant voluntarily acknowledges
and consents to the collection, use, processing and transfer of personal data
as described in this paragraph. 
Participant is not obliged to consent to such collection, use,
processing and transfer of personal data. 
However, failure to provide the consent may affect Participant’s ability
to participate in the Plan.  The Company,
its subsidiaries and its affiliates hold certain personal information about
Participant, including Participant’s name, home address and telephone number,
date of birth, social insurance number or other employee identification number,
salary, nationality, job title, any shares of stock or directorships held in
the Company, details of Participant’s RSUs, all other equity incentive awards
or any other rights or entitlements to Shares in your favor, for the purpose of
managing and administering the Plan (“Data”). 
The Company, its subsidiaries and/or its affiliates will transfer Data
amongst themselves as necessary for the purpose of implementation,
administration and management of Participant’s participation in the Plan, and
the Company, its subsidiaries and/or its affiliates may each further transfer
Data to any third parties assisting the Company in the implementation,
administration and management of the Plan. 
These recipients may be located in the European Economic Area, or
elsewhere throughout the world, such as the United States.  Participant authorizes them to receive,
possess, use, retain and transfer the Data, in electronic or other form, for
the purposes of implementing, administering and managing his or her
participation in the Plan, including any requisite transfer of such Data

as may be required
for the administration of the Plan and/or the subsequent holding of Shares on
Participant’s behalf to a broker or other third party with whom Participant may
elect to deposit any Shares acquired pursuant to the Plan.  Participant may, at any time, review Data,
require any necessary amendments to it or withdraw the consents herein in
writing by contacting the Company; however, withdrawing his or her consent may
affect Participant’s ability to participate in the Plan.  Participant acknowledges and agrees that his
or her consent shall apply to any and all restricted stock unit awards made to
him or her under the Plan or this Agreement, whether now or in the future.

(i)            Capitalized terms used in this
Agreement but not defined herein shall have the same meanings as in the
Plan.  If there is any conflict between
the provisions of this Agreement and the provisions of the Plan, the provisions
of the Plan shall govern, except as otherwise specifically provided herein.

(j)            THE PLAN AND THIS AGREEMENT SHALL BE
GOVERNED BY THE LAWS OF THE STATE OF NEW YORK AND ANY APPLICABLE FEDERAL
LAWS.  INTERPRETATION OF THE PLAN AND
THIS AGREEMENT SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK AND ANY
APPLICABLE FEDERAL LAWS.  ANY LEGAL
PROCEEDING ARISING OUT OF THE PLAN OR THIS AGREEMENT SHALL BE BROUGHT
EXCLUSIVELY IN THE FEDERAL OR STATE COURTS LOCATED IN THE STATE OF NEW YORK.  YOU AGREE TO SUBMIT TO PERSONAL JURISDICTION
AND TO VENUE IN THOSE COURTS.  YOU
FURTHER AGREE TO WAIVE ALL LEGAL CHALLENGES AND DEFENSES TO THE APPROPRIATENESS
OF NEW YORK AS THE SITE OF ANY SUCH LEGAL PROCEEDING AND TO THE APPLICATION OF
THE LAWS OF THE STATE OF NEW YORK AND ANY APPLICABLE FEDERAL LAWS.

*  * 
*  *  *

If
you do not want to accept your RSUs on the terms and conditions set out in this
Agreement, the Plan and/or any related documents, you may choose the “Reject”
button.  Your RSUs will then be cancelled
and no other benefit will be due to you in lieu thereof.  If you do not either “Accept” or “Reject”
your RSUs within 60 days from the Grant Date, we will assume that you want to
accept your RSUs and that you agree to the terms and conditions set out in this
Agreement, the Plan and/or any related documents.

By
choosing the “Accept” button, you accept your RSUs as described above and the
terms and conditions set out in this Agreement, the Plan and any related
documents.  Copies of the Plan and such
related documents are being provided to you as part of this Agreement.

IMS
HEALTH INCORPORATED

David R. Carlucci

Chairman & Chief Executive Officer

Exhibit
10.39 Form C

RESTRICTED STOCK
UNIT GRANT AGREEMENT

RESTRICTED STOCK
UNITS GRANTED UNDER THE

1998 IMS HEALTH INCORPORATED EMPLOYEES’ STOCK INCENTIVE PLAN

This Restricted
Stock Unit Grant Agreement, including the Terms and Conditions provided herewith
(together, the “Agreement”), confirms the grant of Restricted Stock Units (“RSUs”)
as of                                          
(the “Grant Date”) by the Compensation and Benefits Committee (the “Committee”)
of the Board of Directors of IMS Health Incorporated (the “Company”) as
follows:

	
  Participant Granted RSUs:

  	
   

  
	
   

  	
   

  
	
  Number of RSUs
  Granted:

  	
   

  

 

The
RSUs are granted under the 1998 IMS Health Incorporated Employees’ Stock
Incentive Plan (the “Plan”).  The RSUs
are subject to all the terms and conditions of the Plan, which is provided
herewith and incorporated herein by reference, and are subject to the terms and
conditions of this Agreement.

The RSUs will vest
in four equal annual installments beginning on the first anniversary of the
Grant Date if Participant’s employment with the Company or a Subsidiary
continues through the vesting date, except as otherwise provided in the Plan
and this Agreement.

Participant
acknowledges and agrees that (i) until an RSU has become vested in accordance
with Section 2(a) hereof, such RSU will be subject to a risk of forfeiture to
the extent provided in such Section 2, and (ii) until the time each RSU becomes
vested, such RSU shall be generally nontransferable, as provided in Section 3
hereof.

IN WITNESS
WHEREOF, IMS Health Incorporated has caused this Agreement to be executed by
its officer thereunto duly authorized.

By the Company’s signature, and Participant’s
acceptance of these RSUs (as described in the attached Terms and Conditions),
the Company and Participant agree to the terms of this Agreement.  

	
   

  	
  IMS HEALTH INCORPORATED

  
	
   

  	
   

  
	
   

  	
  David R.
  Carlucci

  
	
   

  	
  Chairman &
  Chief Executive Officer

  

 

TERMS AND
CONDITIONS

OF RESTRICTED STOCK UNITS

1.             Restricted Stock Units

Each Restricted
Stock Unit (“RSU”) represents a generally nontransferable, conditional right to
receive one share of the Company’s Common Stock (a “Share”) at a specified
future date, together with a right to receive payments equivalent to dividends
paid on Shares (“Dividend Equivalents”) and other rights, subject to the terms
and conditions of the 1998 IMS Health Incorporated Employees’ Stock Incentive
Plan (the “Plan”) and this Agreement. 
RSUs are bookkeeping units, and do not represent ownership of Shares or
any other equity security.  The Company
shall maintain a bookkeeping account on behalf of Participant (the “Account”)
reflecting the number of RSUs then credited to Participant hereunder as a
result of this grant of RSUs and any crediting of additional RSUs to
Participant pursuant to payments of Dividend Equivalents under Section 5.  For purposes of this Agreement, the term RSUs
includes RSUs as to which the risk of forfeiture under Section 2 has lapsed.

2.             Vesting and Forfeiture

(a)           RSUs granted hereunder shall vest
(meaning that the risk of forfeiture of such RSUs under this Section 2 shall
lapse; such RSUs shall remain subject to Section 6) at the scheduled lapse date
as described on the cover page of this Agreement, except that all RSUs shall
vest on an accelerated basis upon Termination of Employment by reason of death
or Disability.  Each RSU credited as a
result of Dividend Equivalents on a forfeitable RSU and any cash amount payable
as Dividend Equivalents on a forfeitable RSU under Section 5(a) shall vest at
the time of vesting of the forfeitable RSU which gives rise, directly or
indirectly, to the crediting of such Dividend Equivalent RSU or cash.  Each RSU credited as a result of Dividend Equivalents
on a then non-forfeitable RSU under Section 5(a) shall be fully vested and
non-forfeitable from and after the date of such crediting, and any cash amount
credited as Dividend Equivalents on a then non-forfeitable RSU shall be deemed
to be fully vested and non-forfeitable at the time it is credited and shall be
paid at the time of settlement.

(b)           In the event of Participant’s
Termination of Employment, all RSUs that are not vested at or prior to the time
of such Termination shall be forfeited, unless otherwise determined by the
Committee.  Thus, upon Participant’s
voluntary Termination of Employment or a Termination of Employment by the
Company for Cause, unvested RSUs generally will be forfeited.

(c)           For purposes of this Agreement, a
Termination of Employment shall mean a termination of Participant’s employment
with the Company or a subsidiary or affiliate of the Company if, immediately
thereafter, Participant is not employed by any of the Company or its
subsidiaries or affiliates.

(d)           For purposes of this Agreement, Cause
shall have the meaning defined in an employment agreement between the Company
(or a subsidiary or affiliate) and Participant in effect at the time of
Termination of Employment or, if there is no such employment agreement, Cause
shall mean (1) willful malfeasance or willful misconduct by Participant in
connection with his or her employment, (2) continuing failure to perform such
duties as are requested by any employee to whom Participant reports, directly
or indirectly, or by the board of directors of either the Company or the subsidiary
or affiliate that employs

Participant, (3)
failure by Participant to observe policies of the Company or his or her
employer applicable to Participant, or (4) the commission by Participant of (i)
any felony or (ii) any misdemeanor involving moral turpitude.

3.             Nontransferability

Until the time
each RSU becomes vested in accordance with Section 4 below, such RSU shall not
be transferable or assignable other than by will or by the laws of descent and
distribution or to a designated Beneficiary in the event of Participant’s
death, and no such transfer shall be effective to bind the Company unless the
Committee shall have been furnished with a copy of such will, Beneficiary
designation, or such other evidence as the Committee may deem necessary to
establish the validity of the transfer.

4.             Settlement

RSUs granted
hereunder, together with RSUs credited as a result of Dividend Equivalents,
shall be settled by delivery of one Share for each RSU being settled.  Settlement of an RSU granted hereunder shall
occur upon the lapse of the risk of forfeiture of such RSU under Section 2,
within 60 days after such lapse. 
Settlement of RSUs that directly or indirectly result from Dividend
Equivalents on RSUs granted hereunder shall occur at the time of settlement of
the granted RSU.

5.             Dividend Equivalents and
Adjustments

(a)           Dividend Equivalents shall be paid or
credited on RSUs (other than RSUs that, at the relevant record date, previously
have been settled or forfeited) as follows:

(i)                                     Cash Dividends.  If
the Company declares and pays a dividend or distribution on Common Stock in the
form of cash and the record date for such cash dividend is prior to the
settlement of the associated RSU, then a Participant shall be entitled to
Dividend Equivalents calculated at the time of such settlement and credited and
paid in cash at settlement, without interest.

(ii)                                  Non-Share Dividends. 
If the Company declares and pays a dividend or distribution on Common
Stock in the form of property other than Shares, then a number of additional
RSUs shall be credited to Participant’s Account as of the payment date for such
dividend or distribution equal to the number of RSUs credited to the Account as
of the record date for such dividend or distribution multiplied by the Fair
Market Value of such property actually paid as a dividend or distribution on
each outstanding Share at such payment date, divided by the Fair Market Value
of a Share at such payment date.

(iii)                               Common Stock Dividends and Splits.  If the Company declares and pays a dividend
or distribution on Common Stock in the form of additional Shares, or there
occurs a forward split of Common Stock, then a number of additional RSUs shall
be credited to Participant’s Account as of the payment date for such dividend
or distribution or forward split equal to the number of RSUs credited to the
Account as of the record date for such dividend or distribution or split
multiplied by the number of additional Shares actually paid as a dividend or
distribution or issued in such split in respect of each outstanding Share.

(b)           The number of RSUs credited to
Participant’s Account shall be

appropriately
adjusted, in order to prevent dilution or enlargement of Participant’s rights
with respect to RSUs, to reflect any changes in the outstanding Shares
resulting from any event referred to in Section 10(a) of the Plan, taking into
account any RSUs credited to Participant in connection with such event under
Section 5(a) hereof.

6.             Forfeiture of RSUs and Shares
Acquired Upon Prior Vesting and Settlement

The
greatest assets of IMS HEALTH, its subsidiaries and its affiliates (each, an “IMS
HEALTH Company”) are its employees, technology and customers.  In recognition of the increased risk of
unfairly losing any of these assets to its competitors, IMS HEALTH has adopted
the following policy:

If Participant
directly or indirectly engages in any of the “Detrimental Activities” defined
below:

(a)                                  any
unvested RSUs shall automatically be forfeited on the later of the date of
Participant’s Termination of Employment or the date IMS HEALTH becomes aware of
Participant’s Detrimental Activity, without regard to the provisions of Section
2; and

(b)                                 Participant
shall forfeit to the Company any RSUs that vested and the resulting Shares
acquired upon settlement during the one year prior to, or at any time after,
the date of the earliest actual occurrence of Participant’s Detrimental
Activity (the “Forfeiture Period”). 
These Shares shall be forfeited by Participant and are payable to the
Company at the later of the date of Participant’s Termination of Employment or
the date IMS HEALTH becomes aware of Participant’s Detrimental Activity.  If Participant has disposed of such Shares
during the Forfeiture Period, Participant’s obligation to repay Shares upon
such forfeiture will continue (payment of cash or other property is not
permitted), so that Participant will be required to acquire replacement Shares
and deliver them to the Company in settlement of Participant’s forfeiture
obligation without regard to any subsequent market price increase or decrease
from the date of exercise.  If
Participant fails to promptly deliver forfeited Shares and if, apart from this
Agreement, the Company is obligated to pay any cash amount to Participant, the
Company, as a setoff, may use such cash to purchase Shares in the open market
on Participant’s behalf, which Shares will be retained by the Company in
settlement of Participant’s forfeiture obligation hereunder.

Detrimental Activities
are defined as:

·                  using or disclosing any information that has
been treated by an IMS HEALTH Company as confidential or proprietary and is of
competitive advantage to such IMS HEALTH Company, unless Participant is using or disclosing it in the course of Participant’s job with such IMS HEALTH Company;

·                  during
the period beginning the Date of Grant and ending twelve months after
Participant leaves his or her employment with any IMS HEALTH Company (the “Prohibited
Period”), soliciting, inducing, enticing or procuring for anyone other than an
IMS HEALTH Company the trade or business of any entity that was a customer
(including “near-permanent” customers), prospective customer or data supplier
of an IMS HEALTH Company, in order to sell to such customer or prospective
customer, or obtain from such data supplier, the same, similar or related
services IMS HEALTH offers to its customers, or such data supplier provided to
IMS HEALTH, during the period that Participant worked for any IMS HEALTH
Company;

·                  during
the Prohibited Period, soliciting, inducing, enticing or procuring any employee
of any IMS HEALTH Company to leave his or her employment; or employing or

otherwise using
the services of any person who is or was an IMS HEALTH Company employee during
the last twelve months that Participant worked for an IMS HEALTH Company; or

·                  during
the Prohibited Period, directly or indirectly (including without limitation as
an officer, director, employee, advisor, agent, consultant or investor, other
than by the ownership of a passive investment interest of not more than 1% in a
company with publicly traded equity securities), (i) seeking or accepting any
employment or other work with or providing assistance to any person or entity
that offers Competitive Services (as defined below) to any person or entity
that was a customer or potential customer of any IMS HEALTH Company at any time
during the last two years of Participant’s employment with any IMS HEALTH
Company, or (ii) otherwise providing Competitive Services.

For
purposes hereof, “Competitive Services” means engaging in the following
activities anywhere in the world in relation to the pharmaceutical and
healthcare industries (it being understood that the global market in which any
of the businesses of IMS is conducted and to which their goodwill extends is
not limited to any particular region in the world and that given the
informational nature of such businesses, they may be engaged effectively from
any location in the world):

·                  providing
information services for the management of sales forces engaged in the sale of
prescription or over-the-counter drugs, medical devices, or medical or surgical
products;

·                  providing
information services for the measurement of sales force performance or product
performance for prescription or over-the-counter drugs, medical devices, or
medical or surgical products;

·                  creating
or providing physician profiles for purposes of assisting others in the
targeting of promotion or sales activities in relation to prescription or
over-the-counter drugs, medical devices, or medical or surgical products;

·                  creating
or providing micromarketing programs based on prescribing behavior or attitudes
of physicians or other prescribers in relation to prescription or
over-the-counter drugs, medical devices, or medical or surgical products;

·                  creating
or providing market research reports or audits relating to the use, sale,
marketing/promotion, distribution or warehousing of any prescription or
over-the-counter drugs, medical devices, or medical or surgical products;

·                  using
or developing technology, methodologies or processes which have functionality
or produce results similar to the technology, methodologies or processes
employed or offered by IMS HEALTH to process pharmaceutical or healthcare
information, including but not limited to internal processing technology,
decision support tools, data warehousing applications and data mining
applications;

·                  creating
or providing reference files, classification schemes, master files or other
methods of categorizing, classifying, organizing or identifying products,
procedures, medical facilities, pharmacies, warehouses, distributors,
prescribers, pharmacists or other entities, activities or persons associated
with the use, sale, marketing/promotion, distribution or warehousing of any
prescription or over-the-counter drugs, medical devices, or medical or surgical
products; or

·                  providing
market research consulting, sales management consulting, information technology
consulting or market event management consulting, or any other consulting
services in connection with any of the foregoing activities or otherwise
relating to the use, sale, marketing/promotion, distribution or warehousing of
any prescription or over-the-counter drugs, medical devices, or medical or
surgical products.

7.                                       Other
Terms Relating to RSUs

(a)           The number of RSUs credited to a
Participant’s Account shall include fractional RSUs calculated to at least
three decimal places, unless otherwise determined by the Committee.  Upon settlement of RSUs, Participant shall be
paid, in cash, an amount equal to the value of any fractional share that would
have otherwise been deliverable in settlement of such RSUs, unless the Company
arranges to deliver shares to an account of Participant to which fractional
shares may be credited without requiring the Company to in fact issue a fractional
share.

(b)           It shall be a condition to the
obligation of the Company to issue and deliver Shares in settlement of the RSUs
that Participant (or any Beneficiary) pay to the Company (or a subsidiary or
affiliate), upon its demand, such amount as may be requested by the Company for
the purpose of satisfying the minimum statutory withholding liabilities for
federal, state, or local income or other taxes. 
If the amount requested is not paid, the Company may refuse to deliver
the Shares in settlement of the RSUs until such amount is paid.  Unless otherwise determined by the Committee
or unless Participant (or a Beneficiary) has prior to the settlement date made
alternative arrangements satisfactory to the Company to pay withholding taxes
applicable upon settlement, the Company shall withhold from the Shares to be
delivered in settlement of the RSUs that number of Shares having a fair market
value equal to the amount of such tax liability (or as nearly equal as possible
without exceeding the amount of such tax liability).  For this purpose, the fair market value of
the withheld Shares shall be the average high/low sales prices in composite
trading of New York Stock Exchange Listed securities on the day on which the
Shares are withheld.

8.             Miscellaneous

(a)           This Agreement shall be legally
binding when executed by the Company and accepted by Participant as described
below, provided that no election of Participant will be binding unless
Participant has accepted the Agreement and the terms of the Plan (as described below).

(b)           This Agreement shall be binding upon
the heirs, executors, administrators and successors of the parties.  This Agreement constitutes the entire
agreement between the parties with respect to the RSUs, and supersedes any
prior agreements or documents with respect to the RSUs.  No amendment, alteration, suspension,
discontinuation or termination of this Agreement which may impose any
additional obligation upon the Company or impair the rights of Participant with
respect to the RSUs shall be valid unless in each instance such amendment,
alteration, suspension, discontinuation or termination is expressed in a
written instrument duly executed (or accepted electronically, if permitted in
the sole discretion of the Committee) in the name and on behalf of the Company
and by Participant.

(c)           Any Beneficiary designation made by
Participant in accordance with this provision may be changed from time to time,
without the consent of any previously designated Beneficiary (but subject to
any spousal consent as may be required) by filing with the Executive
Compensation & Equity Plans Department a notice of such change.   The change of Beneficiary designation shall
become effective upon receipt by the Executive Compensation & Equity Plans
Department.  In the event Participant’s
Beneficiary would otherwise become entitled to a distribution hereunder, and
all Beneficiaries designated by Participant are not then living, or if no valid
Beneficiary designation is in effect, Participant’s estate or duly authorized
personal representative shall be deemed to have been designated by Participant.

(d)           Any provision for distribution in
settlement of Participant’s Account hereunder shall be by means of bookkeeping
entries on the books of the Company and shall not create in Participant or any
Beneficiary any right to, or claim against any, specific assets of the Company,
nor result in the creation of any trust or escrow account for Participant or
any Beneficiary.  Participant or any
Beneficiary entitled to any distribution hereunder shall be a general creditor
of the Company.

(e)           Participant agrees and acknowledges
that the Plan is discretionary in nature and the Company may amend, cancel or
terminate the Plan at any time.  The
grant of RSUs is a one-time benefit solely offered to employees and does not
create any contractual or other right to receive a grant of RSUs or benefits in
lieu of RSUs in the future.  Future
grants, if any, will be at the sole discretion of the Company, including, but not
limited to, the timing of any grant, the number of RSUs and vesting provisions.

(f)            Participant agrees and acknowledges
that his or her participation in the Plan and his or her execution of this
Agreement is voluntary.  The value of
equity incentive awards generally and Participant’s RSUs specifically is an
extraordinary item of compensation outside the scope of Participant’s
employment contract, if any, and does not constitute compensation of any kind
for services of any kind rendered to the Company (or any of its subsidiaries or
affiliates).  As such, neither equity
incentive awards generally nor Participant’s RSUs specifically are part of
normal or expected compensation for purposes of calculating any termination,
severance, resignation, redundancy, end of service payments, bonuses, long service
awards, pension or retirement benefits, or similar payments.

(g)           Participant acknowledges and agrees
that he or she will have no claim or entitlement (1) to compensation or damages
in consequence of the Termination of Employment with the Company (or any of its
subsidiaries or affiliates) for any reason whatsoever and whether or not in
breach of contract, insofar as such claim or entitlement arises or may arise
from Participant ceasing to have any rights under the Plan or this Agreement,
(2) to vest in his or her RSUs as a result of such Termination of Employment
except as expressly provided in this Agreement, or (3) from the loss or
diminution in value of his or her RSUs; and, upon the grant of Participant’s
RSUs and in partial consideration for his or her participation in the Plan and
this Agreement, Participant shall be deemed irrevocably to have waived any such
claim or entitlement.

(h)           Participant voluntarily acknowledges
and consents to the collection, use, processing and transfer of personal data as
described in this paragraph.  Participant
is not obliged to consent to such collection, use, processing and transfer of
personal data.  However, failure to
provide the consent may affect Participant’s ability to participate in the
Plan.  The Company, its subsidiaries and
its affiliates hold certain personal information about Participant, including
Participant’s name, home address and telephone number, date of birth, social
insurance number or other employee identification number, salary,

nationality, job
title, any shares of stock or directorships held in the Company, details of
Participant’s RSUs, all other equity incentive awards or any other rights or
entitlements to Shares in your favor, for the purpose of managing and
administering the Plan (“Data”).  The
Company, its subsidiaries and/or its affiliates will transfer Data amongst
themselves as necessary for the purpose of implementation, administration and
management of Participant’s participation in the Plan, and the Company, its
subsidiaries and/or its affiliates may each further transfer Data to any third
parties assisting the Company in the implementation, administration and
management of the Plan.  These recipients
may be located in the European Economic Area, or elsewhere throughout the
world, such as the United States. 
Participant authorizes them to receive, possess, use, retain and
transfer the Data, in electronic or other form, for the purposes of
implementing, administering and managing his or her participation in the Plan,
including any requisite transfer of such Data as may be required for the
administration of the Plan and/or the subsequent holding of Shares on
Participant’s behalf to a broker or other third party with whom Participant may
elect to deposit any Shares acquired pursuant to the Plan.  Participant may, at any time, review Data,
require any necessary amendments to it or withdraw the consents herein in
writing by contacting the Company; however, withdrawing his or her consent may
affect Participant’s ability to participate in the Plan.  Participant acknowledges and agrees that his
or her consent shall apply to any and all restricted stock unit awards made to
him or her under the Plan or this Agreement, whether now or in the future.

(i)            Capitalized terms used in this
Agreement but not defined herein shall have the same meanings as in the
Plan.  If there is any conflict between
the provisions of this Agreement and the provisions of the Plan, the provisions
of the Plan shall govern, except as otherwise specifically provided herein.

(j)            THE PLAN AND THIS AGREEMENT SHALL BE
GOVERNED BY THE LAWS OF THE STATE OF NEW YORK AND ANY APPLICABLE FEDERAL
LAWS.  INTERPRETATION OF THE PLAN AND
THIS AGREEMENT SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK AND ANY
APPLICABLE FEDERAL LAWS.  ANY LEGAL
PROCEEDING ARISING OUT OF THE PLAN OR THIS AGREEMENT SHALL BE BROUGHT
EXCLUSIVELY IN THE FEDERAL OR STATE COURTS LOCATED IN THE STATE OF NEW
YORK.  YOU AGREE TO SUBMIT TO PERSONAL
JURISDICTION AND TO VENUE IN THOSE COURTS. 
YOU FURTHER AGREE TO WAIVE ALL LEGAL CHALLENGES AND DEFENSES TO THE
APPROPRIATENESS OF NEW YORK AS THE SITE OF ANY SUCH LEGAL PROCEEDING AND TO THE
APPLICATION OF THE LAWS OF THE STATE OF NEW YORK AND ANY APPLICABLE FEDERAL
LAWS.

*  * 
*  *  *

If
you do not want to accept your RSUs on the terms and conditions set out in this
Agreement, the Plan and/or any related documents, you may choose the “Decline”
button.  Your RSUs will then be cancelled
and no other benefit will be due to you in lieu thereof.  If you do not either “Accept” or “Decline”
your RSUs within 60 days from the Grant Date, we will assume that you want to
accept your RSUs and that you agree to the terms and conditions set out in this
Agreement, the Plan and/or any related documents.

By
choosing the “Accept” button, you accept your RSUs as described above and the
terms and conditions set out in this Agreement, the Plan and any related
documents.  Copies of the Plan and such
related documents are being provided to you as part of this Agreement.

IMS
HEALTH INCORPORATED

David R. Carlucci

Chairman & Chief Executive OfficerExhibit
10.41

TIER-2

CHANGE-IN-CONTROL AGREEMENT

FOR CERTAIN EXECUTIVES

OF IMS HEALTH
INCORPORATED

[Date]

PERSONAL AND CONFIDENTIAL

[Name and Title]

IMS Health Incorporated

Dear
[           ]:

IMS Health Incorporated
(the “Company”) considers it essential to the best interests of its
stockholders to foster the continued employment of key management
personnel.  In this connection, the Board
of Directors of the Company (the “Board”) recognizes that the possibility of a change
in ownership or control of the Company may result in the departure or
distraction of such personnel to the detriment of the Company and its
stockholders.  As you are a skilled and
dedicated executive with important management responsibilities and talents, the
Company believes that its best interests will be served if you are encouraged
to remain with the Company.

The Company has
determined that your ability to perform your responsibilities and utilize your
talents for the benefit of the Company, and the Company’s ability to retain you
as an employee, will be significantly enhanced if you are provided with fair
and reasonable protection from the risks of a change in ownership or control of
the Company.  Accordingly, in order to
induce you to remain in the employ of the Company, you and the Company agree as
follows:

1. Term of Agreement.

(a) Generally.  Except as provided in Section 1(b) hereof,
(i) this Agreement shall be effective as of January 1, 2007 and shall continue
in effect through December 31, 2008, and (ii) commencing on January 1, 2009,
and each January 1 thereafter, this Agreement shall be automatically extended
for one additional year unless, not later than November 30th of the preceding
year, either party to this Agreement gives notice to the other that the
Agreement shall not be extended under this Section 1(a); provided, however,
that no such notice by the Company shall be effective if a Change in Control or
Potential Change in Control (both as defined herein) shall have occurred prior
to the date of such notice.

(b) Upon a Change in
Control.  If a Change in Control
shall have occurred at any time during the period in which this Agreement is
effective, this Agreement shall continue in effect for (i) the remainder of the
month in which the Change in Control occurred and (ii) a term of 24 months
beyond the month in which such Change in Control occurred (such entire period
hereinafter referred to as the “Protected Period”).

  
  
 

2. Change in Control;
Potential Change in Control.

(a) A “Change in Control”
shall be deemed to have occurred if, during the term of this Agreement:

(i) any “Person,” as such
term is used for purposes of Section 13(d) or 14(d) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”) (other than the Company, any
trustee or other fiduciary holding securities under an employee benefit plan of
the Company, or any company owned, directly or indirectly, by the stockholders
of the Company in substantially the same proportions as their ownership of
stock of the Company), becomes the “Beneficial Owner” (as defined in Rule 13d-3
under the Exchange Act), directly or indirectly, of securities of the Company
representing 20% or more of the combined voting power of the Company’s
then-outstanding securities;

(ii) during any period of
twenty-four months (not including any period prior to the effectiveness of this
Agreement), individuals who at the beginning of such period constitute the
Board, and any new director (other than (A) a director nominated by a Person
who has entered into an agreement with the Company to effect a transaction
described in Sections (2)(a)(i), (iii) or (iv) hereof, (B) a director nominated
by any Person (including the Company) who publicly announces an intention to
take or to consider taking actions (including, but not limited to, an actual or
threatened proxy contest) which if consummated would constitute a Change in
Control or (C) a director nominated by any Person who is the Beneficial Owner,
directly or indirectly, of securities of the Company representing 10% or more
of the combined voting power of the Company’s securities) whose election by the
Board or nomination for election by the Company’s stockholders was approved in
advance by a vote of at least two-thirds (2/3) of the directors then still in
office who either were directors at the beginning of the period or whose
election or nomination for election was previously so approved, cease for any
reason to constitute at least a majority thereof;

(iii) any transaction (or
series of transactions) is consummated under which the Company is merged or
consolidated with any other company, other than a merger or consolidation (A)
which would result in the voting securities of the Company outstanding
immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving
entity) more than 66 2/3% of the combined voting power of the voting securities
of the Company or such surviving entity outstanding immediately after such
merger or consolidation and (B) after which no Person holds 20% or more of the
combined voting power of the then-outstanding securities of the Company or such
surviving entity;

(iv) a sale or
disposition by the Company of all or substantially all of the Company’s assets
is consummated or the stockholders of the Company approve a plan of complete
liquidation of the Company; or

(v)  the Board adopts a resolution to the effect
that, for purposes of this Agreement, a Change in Control has occurred.

(b) A “Potential Change
in Control” shall be deemed to have occurred if:

(i) the Company enters
into an agreement, the consummation of which would result in the occurrence of
a Change in Control;

 2
 

(ii) any Person
(including the Company) publicly announces an intention to take or to consider
taking actions which if consummated would constitute a Change in Control; or

(iii) the Board adopts a
resolution to the effect that, for purposes of this Agreement, a Potential
Change in Control has occurred.

(c) Employee Covenants.  You agree that, subject to the terms and
conditions of this Agreement, in the event of a Potential Change in Control,
you will remain in the employ of the Company until the earliest of (i) a date
which is 180 days from the occurrence of such Potential Change in Control, (ii)
the termination of your employment by reason of Disability (as defined herein)
or (iii) the date on which you first become entitled under this Agreement to
receive the benefits provided in Section 3(b) hereof.

(d) Company Covenant
Regarding Potential Change in Control or Change in Control.  In the event of a Potential Change in Control
or a Change in Control, the Company shall, not later than 15 days thereafter,
have established one or more rabbi trusts and shall deposit therein cash in an
amount sufficient to provide for full payment of all potential obligations of
the Company that would arise assuming consummation of a Change in Control and a
subsequent termination of your employment under Section 3(b).  Such rabbi trust(s) shall be irrevocable and
shall provide that the Company may not, directly or indirectly, use or recover
any assets of the trust(s) until such time as all obligations which potentially
could arise hereunder have been settled and paid in full or otherwise
extinguished, subject only to the claims of creditors of the Company in the
event of insolvency or bankruptcy of the Company; provided, however, that if no
Change in Control has occurred within two years after such Potential Change in
Control, such rabbi trust(s) shall at the end of such two-year period become
revocable and may thereafter be revoked by the Company.

3. Termination.

(a) Termination by the
Company for Cause, by You Without Good Reason, or by Reason of Death or
Disability.  If during the Protected
Period your employment by the Company is terminated by the Company for Cause,
by you without Good Reason, or because of your death or Disability, the Company
shall be relieved of its obligation to make any payments to you other than (i)
its payment of amounts otherwise accrued and owing but not yet paid and (ii)
any amounts payable under then-existing employee benefit programs at the time
such amounts are due.

(b) Termination by the
Company Without Cause or by You for Good Reason.  If during the Protected Period your
employment by the Company is terminated by the Company without Cause or by you
for Good Reason, you shall be entitled to the compensation and benefits
described in this Section 3(b).  If your
employment by the Company is terminated prior to a Change in Control at the request
of a Person engaging in a transaction or series of transactions that would
result in a Change in Control, the Protected Period shall commence upon the
subsequent occurrence of a Change in Control, your actual termination shall be
deemed a termination occurring during the Protected Period and covered by this
Section 3(b), your Date of Termination shall be deemed to have occurred
immediately following the Change in Control, and Notice of Termination shall be
deemed to have been given by the Company immediately prior to your actual
termination.  Your continued employment
shall not constitute consent to, or a waiver

 3
 

of rights with respect to, any circumstances
constituting Good Reason hereunder.  The
compensation and benefits provided under this Section 3(b) are as follows:

(i) The Company shall pay
you your full base salary through the Date of Termination at the rate in effect
at the time Notice of Termination is given, on the fifth day following the Date
of Termination, and you shall receive all other amounts to which you are
entitled under any compensation or benefit plan of the Company, at the time
such payments are due in accordance with the terms of such compensation or
benefit plan.

(ii) In the payroll
period next following the payroll period in which your Date of Termination
occurs, the Company shall pay you, in lieu of any further salary, bonus or
severance payments for periods subsequent to the Date of Termination, a lump
sum amount in cash equal to three times the sum of:

(A) the greater of (I)
your annual base salary in effect immediately prior to the Change in Control of
the Company or (II) your annual base salary in effect at the time Notice of
Termination is given; and

(B) the greater of (I)
your annual target bonus for the year in which the Change in Control occurs or,
(II) if no such target bonus has yet been determined for such year, the annual
bonus actually earned by you in the year immediately preceding the year in
which the Change in Control occurs.

(iii) In the payroll
period next following the payroll period in which your Date of Termination
occurs, the Company shall pay to you, in lieu of amounts which may otherwise be
payable to you under the Executive Annual Incentive Plan or any other bonus
plan (the “Bonus Plan”), an amount in cash equal to (A) that portion of your
annual target bonus payable in cash for the year in which the Change in Control
occurs, multiplied by a fraction, (I) the numerator of which equals the number
of full or partial days in such annual performance period during which you were
employed by the Company and (II) the denominator of which is 365, and (B) the
entire target bonus opportunity with respect to each performance period in
progress for any bonus payable to you in stock under all Bonus Plans in effect
at the time of termination.

(iv) The Company shall
provide you with a cash allowance for outplacement and job search activities
(including, but not limited to, office and secretarial expenses) in the amount
of 20% of your annual base salary and annual target bonus taken into account
under Section 3(b)(ii) hereof, provided that (A) such cash allowance
shall not exceed $100,000 and (B) such cash allowance shall apply only to those
costs or obligations that are incurred by you during the 36-month period
following your termination of employment. 
Payments of such cash allowance shall be made on the fifteenth day
following the submission of each receipt to the Company evidencing costs or
obligations incurred by you in connection with outplacement and job search
activities.

(v)  Notwithstanding the provisions of your
Restrictive Covenant Agreement with the Company, your agreement set forth in
such Restrictive Covenant Agreement not to compete with the Company for one
year after your termination of employment shall not apply; however, the other
provisions of your Restrictive Covenant Agreement shall remain in full force
and effect, including without limitation, the non-solicitation, non-disclosure,
confidentiality and non-disparagement covenants set forth therein.

 4
 

(vi)  If you are an expatriate, you will be repatriated,
at the Company’s expense, to your home country or to any other country you
choose provided that the Company’s cost for your repatriation will not exceed
the cost the Company would have incurred had it repatriated you to your home
country.  Your repatriation allowances
and benefits will be as described in the Company’s Long-Term Assignment Policy
but there will be no claw-back of any relocation costs by reason of the early
termination of your assignment.

(vii) During the 36-month
period following your termination of employment, you will receive fully
subsidized COBRA coverage (grossed up for your taxes) under the Company’s
health plan for so long as it is available and thereafter you will be paid cash
payments equivalent on an after-tax basis to the value of the health plan
benefits you would have received under the Company’s health plan had you
continued to be employed during such 36-month period, with such payments to be
made by the Company to you on a monthly basis (it being understood that the Company
payments to you attributable to the health plan benefits will be equal on an
after-tax basis to the monthly premium cost to you to purchase such health plan
benefits separately, which shall not exceed the highest risk premium charged by
a carrier having an investment grade or better credit rating).  You will also receive during such 36-month
period cash payments equivalent on an after-tax basis to the value of the life
insurance benefits you would have received under the Company’s life insurance
plan had you continued to be employed during such 36-month period, with such
payments to be made by the Company to you on a monthly basis (it being
understood that the Company payments to you attributable to the life insurance
plan benefits will be equal on an after-tax basis to the monthly premium cost
to you to purchase such life insurance plan benefits separately, which shall
not exceed the highest risk premium charged by a carrier having an investment
grade or better credit rating). 
Notwithstanding the foregoing, the benefits described in this Section
3(b)(vii) shall constitute secondary coverage with respect to any health or
life insurance benefits actually received by you in connection with any
subsequent employment (or self-employment) during the 36-month period following
your termination.

(viii) When you attain
age 55, if you are eligible to participate in the Company’s retiree health and
life insurance plans, you will receive monthly payments from the Company to
reimburse you for your cost to participate in those plans, grossed up for your
taxes.  If you are not eligible to
participate in the Company’s retiree health and life insurance plans, you will
instead receive cash payments equivalent on an after-tax basis to the value of
the retiree health and life insurance benefits you would have received under
the Company’s retiree health and life insurance plans (providing benefits no
less than those provided in the year in which you first entered into a Change
in Control Agreement with the Company) had you qualified for full retiree
health and life insurance benefits under the Company’s retiree health and life
insurance plans, with such payments to be made by the Company to you on a
monthly basis (it being understood that the Company payments to you attributable
to the health and life insurance benefits will be equal on an after-tax basis
to the monthly premium cost to you to purchase such benefits separately, which
shall not exceed the highest risk premium charged by a carrier having an
investment grade or better credit rating). 
Notwithstanding the foregoing, the benefits described in this Section
3(b)(viii) shall constitute secondary coverage with respect to any health or
life insurance benefits actually received by you in connection with any
subsequent employment (or self-employment) or otherwise following your
attainment of age 55.

(c) Excise Tax.  In the event you become entitled to any
amounts payable in connection with a Change in Control (whether or not such
amounts are payable pursuant to this Agreement) (the “Severance Payments”), if
any of such

 5
 

Severance Payments are subject to the tax (the “Excise
Tax”) imposed by Section 4999 of the Code (or any similar federal, state or
local tax that may hereafter be imposed), the Company shall pay to you at the
time specified herein an additional amount (the “Gross-Up Payment”) such that
the net amount retained by you, after deduction of any Excise Tax on the Total
Payments (as hereinafter defined) and any federal, state and local income tax
and Excise Tax upon the payment provided for by this Section 3(c), shall be
equal to the Total Payments. For purposes of determining whether any of the
Severance Payments will be subject to the Excise Tax and the amount of such
Excise Tax: (i) any other payments or benefits received or to be received by
you in connection with a Change in Control or your termination of employment
(whether pursuant to the terms of this Agreement or any other plan, arrangement
or agreement with the Company, any Person whose actions result in a Change in
Control or any Person affiliated with the Company or such Person) (which,
together with the Severance Payments, constitute the “Total Payments”) shall be
treated as “parachute payments” within the meaning of Section 280G(b)(2) of the
Code, and all “excess parachute payments” within the meaning of Section
280G(b)(1) of the Code shall be treated as subject to the Excise Tax, unless in
the opinion of nationally-recognized tax counsel selected by you such other
payments or benefits (in whole or in part) do not constitute parachute
payments, or such excess parachute payments (in whole or in part) represent
reasonable compensation for services actually rendered within the meaning of
Section 280G(b)(4) of the Code in excess of the base amount within the meaning of
Section 280G(b)(3) of the Code, or are otherwise not subject to the Excise Tax;
(ii) the amount of the Total Payments which shall be treated as subject to the
Excise Tax shall be equal to the lesser of (A) the total amount of the Total
Payments and (B) the amount of excess parachute payments within the meaning of
Section 280G(b)(1) of the Code (after applying Section 3(c)(i) hereof); and
(iii) the value of any non-cash benefits or any deferred payments or benefit
shall be determined by a nationally-recognized accounting firm selected by you
in accordance with the principles of Sections 280G(d)(3) and (4) of the
Code.  For purposes of determining the
amount of the Gross-Up Payment, you shall be deemed to pay federal income taxes
at the highest marginal rate of federal income taxation in the calendar year in
which the Gross-Up Payment is to be made and state and local income taxes at
the highest marginal rate of taxation in the state and locality of your
residence on the Date of Termination, net of the maximum reduction in federal
income taxes which could be obtained from deduction of such state and local
taxes.  In the event that the Excise Tax
is subsequently determined to be less than the amount taken into account hereunder
at the time of termination of your employment, you shall repay to the Company
within ten days after the time that the amount of such reduction in Excise Tax
is finally determined the portion of the Gross-Up Payment attributable to such
reduction (plus the portion of the Gross-Up Payment attributable to the Excise
Tax and federal and state and local income tax imposed on the Gross-Up Payment
being repaid by you if such repayment results in a reduction in Excise Tax
and/or federal and state and local income tax deduction) plus interest on the
amount of such repayment at the rate provided in Section 1274(b)(2)(B) of the
Code.  In the event that the Excise Tax
is determined to exceed the amount taken into account hereunder at the time of
the termination of your employment (including by reason of any payment the
existence or amount of which cannot be determined at the time of the Gross-Up
Payment), the Company shall make an additional gross-up payment in respect of
such excess ten days after the time that the amount of such excess is finally determined.  The payments provided for in this Section
3(c) shall be made on the fifteenth day following your Date of Termination; provided,
however, that if the amount of such payments cannot be finally determined
on or before such day, the Company shall pay you on such day an estimate, as
determined in good faith by the Company, of the minimum amount of such payments
and shall pay the remainder of such payments (together with interest at the
rate provided in Section 1274(b)(2)(B) of the Code) as soon as

 6
 

administratively practicable in compliance with
Section 409A of the Code and the proposed and final Treasury Regulations
thereunder, as the same may be amended from time to time (the “Regulations”)
but in no event later than the thirtieth day after your Date of Termination
subject, however, to any delay in the payment date as a result of Section 3(d)
of this Agreement (relating to the six-month delay in payment of certain
benefits to Specified Employees as required by Section 409A of the Code).  In the event that the amount of the estimated
payments exceeds the amount subsequently determined to have been due, such
excess shall constitute a loan by the Company to you, payable on the fifteenth
day after the demand by the Company (together with interest at the rate
provided in Section 1274(b)(2)(B) of the Code).

(d) Delay in Payment
to Specified Employees.  Anything in
this Agreement to the contrary notwithstanding, payments to be made under this
Agreement upon your termination of employment which are subject to Section 409A
of the Code shall be delayed for six months following such termination of
employment if you are a “Specified Employee” as defined in Section 3(f) on your
Date of Termination.  Any payment due
within such six-month period shall be delayed to the end of such six-month
period. The Company will adjust the payment to reflect the deferred payment
date by multiplying the payment by the product of the six-month CMT Treasury
Bill annualized yield rate as published by the U.S. Treasury for the date on which
such payment would have been made but for the delay multiplied by a fraction,
the numerator of which is the number of days by which such payment was delayed
and the denominator of which is 365. The Company will pay the adjusted payment
at the beginning of the seventh month following your Date of Termination.
Notwithstanding the foregoing, if calculation of the amounts payable by any
payment date specified in this Section 3(d) is not administratively practicable
due to events beyond your control (or the control of your beneficiary or
estate) and for reasons that are commercially reasonable, payment will be made
as soon as administratively practicable in compliance with Section 409A of the
Code and the Regulations.  In the event
of your death during such six-month period, payment will be made in the payroll
period next following the payroll period in which your death occurs.

(e) Notice.  During the Protected Period, any purported
termination of your employment by the Company or by you shall be communicated
by written Notice of Termination to the other party hereto.

(f) Certain
Definitions.  Except as otherwise
indicated in this Agreement, all definitions in this Section 3(f) shall be
applicable during the Protected Period only.

(i) Cause.  “Cause” shall mean termination on account of
(A) the willful and continued failure by you to substantially perform your
duties with the Company (other than any such failure resulting from your
incapacity due to physical or mental illness or Disability or any failure after
the issuance of a Notice of Termination by you for Good Reason) which failure
is demonstrably and materially damaging to the financial condition or
reputation of the Company and/or its subsidiaries, and which failure continues
more than 48 hours after a written demand for substantial performance is
delivered to you by the Board, which demand specifically identifies the manner
in which the Board believes that you have not substantially performed your
duties and the demonstrable and material damage caused thereby or (B) the
willful engaging by you in conduct which is demonstrably and materially
injurious to the Company, monetarily or otherwise.  No act, or failure to act, on your part shall
be deemed “willful” unless done, or omitted to be done, by you not in good
faith and without reasonable belief that your action or omission was

 7
 

in the best interest of the Company.  Notwithstanding the foregoing, you shall not
be deemed to have been terminated for Cause unless and until there shall have
been delivered to you a copy of the resolution duly adopted by the affirmative
vote of not less than three-quarters (3/4) of the entire membership of the
Board at a meeting of the Board (after reasonable notice to you and an
opportunity for you, together with your counsel, to be heard before the Board)
finding that, in the good faith opinion of the Board, you were guilty of
conduct set forth above in this Section 3(f)(i) and specifying the particulars
thereof in detail.

(ii) Date of
Termination.  “Date of Termination”
shall mean (A) if your employment is terminated for Disability, 30 days after
Notice of Termination is given (provided that you shall not have returned to
the full-time performance of your duties during such 30-day period) or (B) if
your employment is terminated for any other reason, the date specified in the
Notice of Termination (which, in the case of a termination for Cause, shall not
be less than 30 days from the date such Notice of Termination is given and, in
the case of a termination for Good Reason, shall not be less than 15 nor more
than 60 days from the date such Notice of Termination is given).

(iii) Disability.  “Disability” shall mean your absence from the
full-time performance of your duties with the Company for six consecutive
months as a result of your incapacity due to physical or mental illness or
disability, and within 30 days after written Notice of Termination is
thereafter given you shall not have returned to the full-time performance of
your duties.

(iv) Good Reason.  “Good Reason” shall mean, without your
express written consent, the occurrence upon or after a Change in Control of
any of the following circumstances unless, in the case of Sections 3(f)(iv)(A),
(D), (F) or (G) hereof, such circumstances are fully corrected prior to the
Date of Termination specified in the Notice of Termination given in respect
thereof:

(A) the assignment to you
of any duties inconsistent with the position in the Company that you held
immediately prior to the Change in Control, or an adverse alteration in the
nature or status of your responsibilities or the conditions of your employment
from those in effect immediately prior to such Change in Control;

(B) a reduction by the
Company in your annual base salary, any target bonus or perquisites as in
effect immediately prior to the Change in Control or as the same may be
increased from time to time except for across-the-board perquisite reductions
similarly affecting all senior executives of the Company and all senior
executives of any Person in control of the Company;

(C) the relocation of the
principle place of your employment to a location more than 50 miles from the
location of such place of employment on the date of this Agreement except for
required travel on the Company’s business to an extent substantially consistent
with your business travel obligations prior to the Change in Control;

(D) the failure by the
Company to pay to you any portion of your compensation or to pay to you any
portion of an installment of deferred compensation under any deferred
compensation program of the Company within seven days of the date such
compensation is due;

(E) the failure by the
Company to continue in effect any material compensation or benefit plan in
which you participated immediately prior to

 8
 

the Change in Control, unless an equitable arrangement
(embodied in an ongoing substitute or alternative plan) has been made with
respect to such plan, or the failure by the Company to continue your
participation therein (or in such substitute or alternative plan) on a basis
not materially less favorable, both in terms of the amounts of benefits
provided and the level of your participation relative to other participants, as
existed at the time of the Change in Control;

(F) the failure of the
Company to obtain a satisfactory agreement from any successor to assume and
agree to perform this Agreement, as contemplated in Section 7 hereof; or

(G) any purported
termination of your employment that is not effected pursuant to a Notice of
Termination satisfying the requirements of Section 3(f)(v) (and, if applicable,
the requirements of Section 3(f)(i) hereof), which purported termination shall
not be effective for purposes of this Agreement.

(v) Notice of
Termination.  “Notice of Termination”
shall mean notice indicating the specific termination provision in this
Agreement relied upon and setting forth in reasonable detail the facts and
circumstances claimed to provide a basis for termination of your employment
under the provision so indicated.

(vi) Specified
Employee. “Specified Employee” shall mean an employee of the Company who
satisfies the requirements for being designated a “key employee” under Section
416(i)(1)(A)(i), (ii) or (iii) of the Code without regard to Section 416(i)(5)
of the Code at any time during a calendar year, in which case such employee
shall be considered a Specified Employee for the twelve-month period beginning
on the first day of the fourth month immediately following the end of such
calendar year. Notwithstanding the foregoing, all employees who are nonresident
aliens during an entire calendar year are excluded for purposes of determining
which employees meet the requirements of Section 416(i)(1)(A)(i), (ii) or (iii)
of the Code without regard to Section 416(i)(5) of the Code for such calendar
year. The term “nonresident alien” as used herein shall have the meaning set
forth in Regulations Section 1.409A-1(j). 
In the event of any corporate spinoff or merger, the determination of
which employees meet the requirements of Section 416(i)(1)(A)(i), (ii) or (iii)
of the Code without regard to Section 416(i)(5) of the Code for any calendar
year shall be determined in accordance with Regulations Section 1.409A-1(i)(2).

4. Mitigation.  Except as provided in Sections 3(b)(vii) and
(viii) and Section 6 hereof, you shall not be required to mitigate the amount
of any payment provided for under this Agreement by seeking other employment or
otherwise, nor shall the amount of any payment or benefit provided for under
this Agreement be reduced by any compensation earned by you as the result of employment
by another employer, by retirement benefits, by offset against any amount
claimed to be owed by you to the Company, or otherwise.

5.  Release of Employment Claims.  You agree, as a condition to your receipt of
the compensation and benefits provided for under this Agreement, that you will
execute a general release agreement, in substantially the form set forth as
Attachment A to this Agreement, releasing any and all claims arising out of
your employment other than: (a) the enforcement of this Agreement; (b) with
respect to vested rights or rights provided for under any benefit plan or
arrangement of the Company; or (c) rights to indemnification under any
agreement, law, Company organizational document or policy, or otherwise.

 9
 

6.  Forfeiture.  Except as otherwise provided in Section
3(b)(v) of this Agreement, if you willfully and materially fail to comply with
the terms of your Restrictive Covenant Agreement with the Company or if you
willfully and materially fail to comply with Section 2(c) or Section 5 of this
Agreement, all compensation and benefits provided for under this Agreement
shall be immediately forfeited. Notwithstanding the foregoing, you shall not
forfeit any compensation or benefits provided for under this Agreement unless
and until there shall have been delivered to you, within six months after the
Board (a) had knowledge of conduct or an event allegedly constituting grounds
for such forfeiture and (b) had reason to believe that such conduct or event
could be grounds for such forfeiture, a copy of a resolution duly adopted by a
majority affirmative vote of the membership of the Board at a meeting of the
Board called and held for such purpose (after giving you reasonable notice
specifying the nature of the grounds for such forfeiture and not less than 30
days to correct the acts or omissions complained of, if correctable, and
affording you the opportunity, together with your counsel, to be heard before
the Board) finding that, in the good faith opinion of the Board, you have
engaged and continue to engage in conduct which constitutes grounds for
forfeiture of your compensation and benefits under this Agreement; provided,
however, that in the event that you shall have already received any
compensation or benefits under this Agreement before the Board makes the
determination described in this sentence, you shall immediately reimburse the
Company for such compensation and/or benefits following such determination by
the Board. The forfeiture of any compensation or benefits provided for under
this Agreement by reason of this Section 6 shall apply to such compensation and
benefits notwithstanding any other term or provision of this Agreement or any
other agreement or plan.

7. Successors; Binding
Agreement.

(a) The Company shall
require any successor (whether direct or indirect, by purchase, merger,
consolidation or otherwise) to all or substantially all of the business and/or
assets of the Company to expressly assume and agree to perform this Agreement
in the same manner and to the same extent that the Company would be required to
perform it if no such succession had taken place.  As used in this Agreement, “Company” shall
mean the Company as hereinbefore defined and any successor to its business
and/or assets as aforesaid which assumes and agrees to perform this Agreement
by operation of law, or otherwise.

(b) This Agreement shall
inure to the benefit of and be enforceable by you and your personal or legal
representatives, executors, administrators, successors, heirs, distributees,
devisees and legatees.  In the event of
your death, all amounts otherwise payable to you hereunder shall, unless
otherwise provided herein, be paid in accordance with the terms of this
Agreement to your devisee, legatee or other designee or, if there is no such
designee, to your estate.

8. Notice.  Notices and all other communications provided
for in this Agreement shall be in writing and shall be deemed to have been duly
given when (a) personally delivered or (b) mailed by United States certified or
registered mail, return receipt requested, postage prepaid, addressed to the
respective addresses set forth on the first page of this Agreement; provided
that all notice to the Company shall be directed to the attention of the
Board with a copy to the General Counsel of the Company, or to such other
address as either party may have furnished to the other in writing in
accordance herewith, except that notice of change of address shall be effective
only upon receipt.

9. Miscellaneous.  No provision of this Agreement may be
modified, waived or discharged unless such waiver, modification or discharge is
agreed to in writing and

 10
 

signed by you and such officer as may be designated by
the Board.  No waiver by either party
hereto at any time of any breach by the other party hereto of, or compliance
with, any condition or provision of this Agreement to be performed by such
other party shall be deemed a waiver of similar or dissimilar provisions or
conditions at the time or at any prior or subsequent time.  Any payments provided for hereunder shall be
paid net of any applicable withholding required under federal, state or local
law.  The obligations of the Company
under this Agreement shall survive the expiration of this Agreement to the
extent necessary to give effect to this Agreement.

10. Validity.  The invalidity or unenforceability of any
provision of this Agreement shall not affect the validity or enforceability of
any other provision of this Agreement, which shall remain in full force and
effect.

11. Counterparts.  This Agreement may be executed in
counterparts, each of which shall be deemed to be an original but all of which
together will constitute one and the same instrument.

12. Entire Agreement.  This Agreement sets forth the entire
agreement of the parties hereto in respect of the subject matter contained
herein and during the term of this Agreement supersedes the provisions of all
prior agreements, promises, covenants, arrangements, communications,
representations or warranties, whether oral or written, by any officer,
employee or representative of any party hereof with respect to the subject
matter contained herein.  No agreements
or representations, oral or otherwise, express or implied, with respect to the
subject matter hereof have been made by either party which are not expressly
set forth in this Agreement. 
Notwithstanding anything to the contrary in this Agreement, the
procedural provisions of this Agreement shall apply to all benefits payable as
a result of a Change in Control (or other change in control) under any employee
benefit plan, agreement, program, policy or arrangement of the Company.  The foregoing notwithstanding, in the event
of any conflict or ambiguity between this Agreement and any employment
agreement executed by you and the Company, the provisions of such employment
agreement shall govern; but no payment or benefit under this Agreement shall be
made or extended which duplicates any payment or benefit under any such
employment agreement.

13.  Governing Law.    This Agreement is
governed by and is to be construed, administered, and enforced in accordance
with the laws of the State of Connecticut, without regard to conflicts of law
principles. If under the governing law, any portion of this Agreement is at any
time deemed to be in conflict with any applicable statute, rule, regulation,
ordinance, or other principle of law, such portion shall be deemed to be
modified or altered to the extent necessary to conform thereto or, if that is
not possible, to be omitted from this Agreement. The invalidity of any such
portion shall not affect the force, effect, and validity of the remaining
portion hereof. Anything in this Agreement to the contrary notwithstanding, the
terms of this Agreement shall be interpreted and applied in a manner consistent
with the requirements of Section 409A of the Code and the Regulations
thereunder and the Company shall have no right to accelerate or make any
payment under this Agreement except to the extent permitted under Section 409A
of the Code.  The Company shall have no
obligation, however, to reimburse you for any tax penalty or interest payable
or provide a gross-up payment in connection with any tax liability you may
incur under Section 409A of the Code except that this provision shall not apply
in the event of the Company’s negligence or willful disregard in interpreting
the application of Section 409A of the Code to this Agreement which negligence
or willful disregard causes you to become subject to a tax penalty or interest
payable under Section 409A of the Code nor shall

 11
 

this provision be interpreted to limit any gross-up
payable to you under Section 3(c) of this Agreement.

14.    Reimbursement of
Expenses in Enforcing Rights.    All
reasonable costs and expenses (including fees and disbursements of counsel)
incurred by you in seeking to interpret this Agreement or enforce rights
pursuant to this Agreement shall be paid on behalf of or reimbursed to you
promptly by the Company, whether or not you are successful in asserting such
rights; provided, however, that no reimbursement shall be made of such expenses
relating to any unsuccessful assertion of rights if and to the extent that your
assertion of such rights was in bad faith or frivolous, as determined by
arbitrators in accordance with Section 15 or a court having jurisdiction
over the matter.  Any such payment or
reimbursement shall be made in a lump sum in the month next following the month
in which such costs and expenses are incurred subject to your submission of
receipts for such expenses.

15.    Arbitration.    Any dispute or
controversy arising under or in connection with this Agreement shall be settled
exclusively by arbitration in Fairfield, Connecticut by three arbitrators in
accordance with the National Rules for the Resolution of Employment
Disputes of the American Arbitration Association in effect at the time of
submission to arbitration. Judgment may be entered on the arbitrators’ award in
any court having jurisdiction. For purposes of entering any judgment upon an
award rendered by the arbitrators, the Company and you hereby consent to the
jurisdiction of any or all of the following courts: (a) the United States
District Court for the District of Connecticut, (b) any of the courts of
the State of Connecticut, or (c) any other court having jurisdiction. The
Company and you further agree that any service of process or notice
requirements in any such proceeding shall be satisfied if the rules of
such court relating thereto have been substantially satisfied. The Company and
you hereby waive, to the fullest extent permitted by applicable law, any
objection which it may now or hereafter have to such jurisdiction and any
defense of inconvenient forum. The Company and you hereby agree that a judgment
upon an award rendered by the arbitrators may be enforced in other
jurisdictions by suit on the judgment or in any other manner provided by law.
Subject to Section 14, the Company shall bear all costs and expenses arising in
connection with any arbitration proceeding pursuant to this Section 15 and
shall pay such costs and expenses in the tax year in which incurred.
Notwithstanding any provision in this Section 15, you shall be paid during
the pendency of any dispute or controversy arising under or in connection with
this Agreement.

16.    Interest on Unpaid
Amounts.    Any
amount which has become payable pursuant to the terms of this Agreement or any
decision by arbitrators or judgment by a court of law pursuant to
Section 15 but which has not been timely paid shall bear interest at the
prime rate in effect at the time such amount first becomes payable, as quoted
by the Company’s principal bank, except as otherwise provided in Section 3(d)
of this Agreement (concerning interest payable with respect to delayed payments
under Section 409A of the Code).

 12
 

If this letter sets forth our agreement on the subject
matter hereof, kindly sign and return to the Company the enclosed copy of this
letter, which will then constitute our agreement on this subject.

	
  

  	
   

  	
  IMS HEALTH INCORPORATED

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  Chairman and Chief Executive Officer

  

 

	
  Agreed to this                                      
  day

  	
   

  
	
   

  	
   

  
	
  of                                                      ,
  2007.

  	
   

  
	
   

  

 

 13
 

ATTACHMENT
A

RELEASE

We advise you to consult an attorney before you sign
this Release.  You have until the date
which is seven (7) days after the Release is signed and returned to IMS Health
Incorporated to change your mind and revoke your Release.  Your Release shall not become effective or enforceable
until after that date.

In consideration for the benefits provided under your
Change-in-Control Agreement with IMS Health Incorporated (the “Agreement”), by
your signature below, you, for yourself and on behalf of your heirs, executors,
agents, representatives, successors and assigns, hereby release and forever
discharge IMS Health Incorporated, its past and present parent corporations,
subsidiaries, divisions, subdivisions, affiliates and related companies
(collectively, the “Company”) and the Company’s past, present and future
agents, directors, officers, employees, representatives, assigns, stockholders,
attorneys, agents, insurers, employee benefit programs (and the trustees,
administrators, fiduciaries and insurers of such programs), and any other
persons acting by, through, under or in concert with any of the persons or
entities listed herein, and their successors (hereinafter “those associated
with the Company”) and with respect to any and all claims, demands, actions and
liabilities, whether in law or equity, which you may have against the Company
or those associated with the Company of whatever kind, including but not
limited to those arising out of your employment with the Company or the
termination of that employment.  You
agree that this Release covers, but is not limited to, claims arising under the
Age Discrimination in Employment Act of 1967, 29 U.S.C. § 621 et seq., Title
VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., the Americans
with Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., the Fair Labor
Standards Act, 29 U.S.C. § 201 et seq., the Employee Retirement Income Security
Act of 1974, 29 U.S.C. § 1001 et seq., the Family and Medical Leave Act of 1993
and any local, state or federal law, regulation or order providing workers’
compensation benefits, restricting an employer’s right to terminate employees
or otherwise regulating employment, enforcing express or implied employment
contracts or requiring an employer to deal with employees fairly or in good
faith, or dealing with discrimination in employment on the basis of sex, race,
color, national origin, veteran status, marital status, religion, disability,
handicap, or age.  You also agree that
this Release includes claims based on wrongful termination of employment,
breach of contract (express or implied), tort, or claims otherwise related to
your employment or termination of employment with the Company and any claim for
attorneys’ fees, expenses or costs of litigation.

This Release covers all claims based on any facts or
events, whether known or unknown by you, that occurred on or before the date of
this Release. You expressly waive all rights you might have under any law that
is intended to protect you from waiving unknown claims and by your signature
below indicate your understanding of the significance of doing so. Examples of
released claims include, but are not limited to:  (a) claims that in any way relate to your
employment with the Company, or the termination of that employment, such as
claims for compensation, bonuses, commissions, lost wages, or unused accrued
vacation or sick pay (other than under your Agreement); (b) claims that in any
way relate to the design or administration of any employee benefit program; (c)
claims that you have irrevocable or vested rights to severance or similar
benefits (other than under your Agreement) or to post-employment health or
group insurance benefits (other than under your Agreement); (d) any claim, such
as a benefit claim, that was explicitly or implicitly denied before you signed
this Release; (e) any claim you might have for extra benefits as a consequence
of payments you receive because of signing this Release; or (f) any claim to
attorneys’ fees or other indemnities. 
Except to enforce your Agreement or this Release, you agree that you
will never commence, prosecute, or cause to be commenced or

 14
 

prosecuted any lawsuit or proceeding of any kind
against the Company or those associated with the Company in any forum and agree
to withdraw with prejudice all complaints or charges, if any, that you have
filed against the Company or those associated with the Company.

Anything in this Release to the contrary
notwithstanding, this Release does not include a release of:  (i) any of your rights under the
Agreement;  (ii) any rights you may have
to indemnification under any agreement, law, Company organizational document or
policy, or otherwise; (iii) any rights you may have to benefits under the
Company’s benefit plans except as otherwise provided in your Agreement or
claims specifically identified in this Release; (iv) any rights or claims under
the Age Discrimination in Employment Act or any other law that arise after you
sign this Release; or (iii) your right to enforce this Release or any of the
foregoing items described in this paragraph.

By signing this Release, you further agree as follows:

i.              You
have read this Release carefully and fully understand its terms;

ii.             You
have had at least twenty-one (21) days to consider the terms of the Release;

iii.            You
have seven (7) days from the date you sign this Release to revoke it by written
notification to the Company.  After this
seven (7)-day period, this Release is final and binding and may not be revoked;

iv.            You
have been advised to seek legal counsel and have had an opportunity to do so;

v.             You
would not otherwise be entitled to the benefits provided under your Agreement
had you not agreed to execute this Release; and

vi.            Your
agreement to the terms set forth above is voluntary.

(The remainder of this page was intentionally left blank)

 15

TIER-3

CHANGE-IN-CONTROL AGREEMENT

FOR CERTAIN EXECUTIVES

OF IMS HEALTH
INCORPORATED

[Date]

PERSONAL AND CONFIDENTIAL

[Name and Title]

IMS Health Incorporated

Dear [              ]:

IMS Health Incorporated
(the “Company”) considers it essential to the best interests of its
stockholders to foster the continued employment of key management
personnel.  In this connection, the Board
of Directors of the Company (the “Board”) recognizes that the possibility of a
change in ownership or control of the Company may result in the departure or
distraction of such personnel to the detriment of the Company and its
stockholders.  As you are a skilled and
dedicated executive with important management responsibilities and talents, the
Company believes that its best interests will be served if you are encouraged
to remain with the Company.

The Company has
determined that your ability to perform your responsibilities and utilize your
talents for the benefit of the Company, and the Company’s ability to retain you
as an employee, will be significantly enhanced if you are provided with fair
and reasonable protection from the risks of a change in ownership or control of
the Company.  Accordingly, in order to
induce you to remain in the employ of the Company, you and the Company agree as
follows:

1. Term of Agreement.

(a) Generally.  Except as provided in Section 1(b) hereof,
(i) this Agreement shall be effective as of January 1, 2007 and shall continue
in effect through December 31, 2008, and (ii) commencing on January 1, 2009,
and each January 1 thereafter, this Agreement shall be automatically extended
for one additional year unless, not later than November 30th of the preceding
year, either party to this Agreement gives notice to the other that the
Agreement shall not be extended under this Section 1(a); provided, however,
that no such notice by the Company shall be effective if a Change in Control or
Potential Change in Control (both as defined herein) shall have occurred prior
to the date of such notice.

(b) Upon a Change in
Control.  If a Change in Control
shall have occurred at any time during the period in which this Agreement is
effective, this Agreement shall continue in effect for (i) the remainder of the
month in which the Change in Control occurred and (ii) a term of 24 months
beyond the month in which such Change in Control occurred (such entire period
hereinafter referred to as the “Protected Period”).

  
  
 

2. Change in Control;
Potential Change in Control.

(a) A “Change in Control”
shall be deemed to have occurred if, during the term of this Agreement:

(i) any “Person,” as such
term is used for purposes of Section 13(d) or 14(d) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”) (other than the Company, any
trustee or other fiduciary holding securities under an employee benefit plan of
the Company, or any company owned, directly or indirectly, by the stockholders
of the Company in substantially the same proportions as their ownership of
stock of the Company), becomes the “Beneficial Owner” (as defined in Rule 13d-3
under the Exchange Act), directly or indirectly, of securities of the Company
representing 20% or more of the combined voting power of the Company’s
then-outstanding securities;

(ii) during any period of
twenty-four months (not including any period prior to the effectiveness of this
Agreement), individuals who at the beginning of such period constitute the
Board, and any new director (other than (A) a director nominated by a Person
who has entered into an agreement with the Company to effect a transaction
described in Sections (2)(a)(i), (iii) or (iv) hereof, (B) a director nominated
by any Person (including the Company) who publicly announces an intention to
take or to consider taking actions (including, but not limited to, an actual or
threatened proxy contest) which if consummated would constitute a Change in
Control or (C) a director nominated by any Person who is the Beneficial Owner,
directly or indirectly, of securities of the Company representing 10% or more
of the combined voting power of the Company’s securities) whose election by the
Board or nomination for election by the Company’s stockholders was approved in
advance by a vote of at least two-thirds (2/3) of the directors then still in
office who either were directors at the beginning of the period or whose
election or nomination for election was previously so approved, cease for any
reason to constitute at least a majority thereof;

(iii) any transaction (or
series of transactions) is consummated under which the Company is merged or
consolidated with any other company, other than a merger or consolidation (A)
which would result in the voting securities of the Company outstanding
immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving
entity) more than 66 2/3% of the combined voting power of the voting securities
of the Company or such surviving entity outstanding immediately after such
merger or consolidation and (B) after which no Person holds 20% or more of the
combined voting power of the then-outstanding securities of the Company or such
surviving entity;

(iv) a sale or
disposition by the Company of all or substantially all of the Company’s assets
is consummated or the stockholders of the Company approve a plan of complete
liquidation of the Company; or

(v) the Board adopts a
resolution to the effect that, for purposes of this Agreement, a Change in
Control has occurred.

(b) A “Potential Change
in Control” shall be deemed to have occurred if:

(i) the Company enters
into an agreement, the consummation of which would result in the occurrence of
a Change in Control;

 2
 

(ii) any Person
(including the Company) publicly announces an intention to take or to consider
taking actions which if consummated would constitute a Change in Control; or

(iii) the Board adopts a
resolution to the effect that, for purposes of this Agreement, a Potential
Change in Control has occurred.

(c) Employee Covenants.  You agree that, subject to the terms and
conditions of this Agreement, in the event of a Potential Change in Control,
you will remain in the employ of the Company until the earliest of (i) a date
which is 180 days from the occurrence of such Potential Change in Control, (ii)
the termination of your employment by reason of Disability (as defined herein)
or (iii) the date on which you first become entitled under this Agreement to
receive the benefits provided in Section 3(b) hereof.

(d) Company Covenant
Regarding Potential Change in Control or Change in Control.  In the event of a Potential Change in Control
or a Change in Control, the Company shall, not later than 15 days thereafter,
have established one or more rabbi trusts and shall deposit therein cash in an
amount sufficient to provide for full payment of all potential obligations of
the Company that would arise assuming consummation of a Change in Control and a
subsequent termination of your employment under Section 3(b).  Such rabbi trust(s) shall be irrevocable and
shall provide that the Company may not, directly or indirectly, use or recover
any assets of the trust(s) until such time as all obligations which potentially
could arise hereunder have been settled and paid in full or otherwise
extinguished, subject only to the claims of creditors of the Company in the
event of insolvency or bankruptcy of the Company; provided, however, that if no
Change in Control has occurred within two years after such Potential Change in
Control, such rabbi trust(s) shall at the end of such two-year period become
revocable and may thereafter be revoked by the Company.

3. Termination.

(a) Termination by the
Company for Cause, by You Without Good Reason, or by Reason of Death or
Disability.  If during the Protected
Period your employment by the Company is terminated by the Company for Cause, by
you without Good Reason, or because of your death or Disability, the Company
shall be relieved of its obligation to make any payments to you other than (i)
its payment of amounts otherwise accrued and owing but not yet paid and (ii)
any amounts payable under then-existing employee benefit programs at the time
such amounts are due.

(b) Termination by the
Company Without Cause or by You for Good Reason.  If during the Protected Period your
employment by the Company is terminated by the Company without Cause or by you
for Good Reason, you shall be entitled to the compensation and benefits
described in this Section 3(b).  If your
employment by the Company is terminated prior to a Change in Control at the
request of a Person engaging in a transaction or series of transactions that
would result in a Change in Control, the Protected Period shall commence upon
the subsequent occurrence of a Change in Control, your actual termination shall
be deemed a termination occurring during the Protected Period and covered by
this Section 3(b), your Date of Termination shall be deemed to have occurred
immediately following the Change in Control, and Notice of Termination shall be
deemed to have been given by the Company immediately prior to your actual
termination.  Your continued employment
shall not constitute consent to, or a waiver

 3
 

of rights with respect to, any circumstances
constituting Good Reason hereunder.  The
compensation and benefits provided under this Section 3(b) are as follows:

(i) The Company shall pay
you your full base salary through the Date of Termination at the rate in effect
at the time Notice of Termination is given, on the fifth day following the Date
of Termination, and you shall receive all other amounts to which you are
entitled under any compensation or benefit plan of the Company, at the time
such payments are due in accordance with the terms of such compensation or
benefit plan.

(ii) In the payroll
period next following the payroll period in which your Date of Termination
occurs, the Company shall pay you, in lieu of any further salary, bonus or
severance payments for periods subsequent to the Date of Termination, a lump
sum amount in cash equal to two times the sum of:

(A) the greater of (I)
your annual base salary in effect immediately prior to the Change in Control of
the Company or (II) your annual base salary in effect at the time Notice of
Termination is given; and

(B) the greater of (I)
your annual target bonus for the year in which the Change in Control occurs or,
(II) if no such target bonus has yet been determined for such year, the annual
bonus actually earned by you in the year immediately preceding the year in
which the Change in Control occurs.

(iii) In the payroll
period next following the payroll period in which your Date of Termination
occurs, the Company shall pay to you, in lieu of amounts which may otherwise be
payable to you under the Executive Annual Incentive Plan or any other bonus
plan (the “Bonus Plan”), an amount in cash equal to (A) that portion of your
annual target bonus payable in cash for the year in which the Change in Control
occurs, multiplied by a fraction, (I) the numerator of which equals the number
of full or partial days in such annual performance period during which you were
employed by the Company and (II) the denominator of which is 365, and (B) the
entire target bonus opportunity with respect to each performance period in
progress for any bonus payable to you in stock under all Bonus Plans in effect
at the time of termination.

(iv) The Company shall
provide you with a cash allowance for outplacement and job search activities
(including, but not limited to, office and secretarial expenses) in the amount
of 20% of your annual base salary and annual target bonus taken into account
under Section 3(b)(ii) hereof, provided that (A) such cash allowance
shall not exceed $100,000 and (B) such cash allowance shall apply only to those
costs or obligations that are incurred by you during the 24-month period
following your termination of employment. 
Payments of such cash allowance shall be made on the fifteenth day
following the submission of each receipt to the Company evidencing costs or
obligations incurred by you in connection with outplacement and job search
activities.

(v) Notwithstanding the
provisions of your Restrictive Covenant Agreement with the Company, your
agreement set forth in such Restrictive Covenant Agreement not to compete with
the Company for one year after your termination of employment shall not apply;
however, the other provisions of your Restrictive Covenant Agreement shall
remain in full force and effect, including without limitation, the
non-solicitation, non-disclosure, confidentiality and non-disparagement
covenants set forth therein.

 4
 

(vi) If you are an
expatriate, you will be repatriated, at the Company’s expense, to your home
country or to any other country you choose provided that the Company’s cost for
your repatriation will not exceed the cost the Company would have incurred had
it repatriated you to your home country. 
Your repatriation allowances and benefits will be as described in the
Company’s Long-Term Assignment Policy but there will be no claw-back of any
relocation costs by reason of the early termination of your assignment.

(vii) During the 24-month
period following your termination of employment, you will receive fully
subsidized COBRA coverage (grossed up for your taxes) under the Company’s
health plan for so long as it is available and thereafter you will be paid cash
payments equivalent on an after-tax basis to the value of the health plan
benefits you would have received under the Company’s health plan had you
continued to be employed during such 24-month period, with such payments to be
made by the Company to you on a monthly basis (it being understood that the
Company payments to you attributable to the health plan benefits will be equal
on an after-tax basis to the monthly premium cost to you to purchase such
health plan benefits separately, which shall not exceed the highest risk
premium charged by a carrier having an investment grade or better credit
rating).  You will also receive during
such 24-month period cash payments equivalent on an after-tax basis to the
value of the life insurance benefits you would have received under the
Company’s life insurance plan had you continued to be employed during such
24-month period, with such payments to be made by the Company to you on a
monthly basis (it being understood that the Company payments to you
attributable to the life insurance plan benefits will be equal on an after-tax
basis to the monthly premium cost to you to purchase such life insurance plan
benefits separately, which shall not exceed the highest risk premium charged by
a carrier having an investment grade or better credit rating).  Notwithstanding the foregoing, the benefits
described in this Section 3(b)(vii) shall constitute secondary coverage with
respect to any health or life insurance benefits actually received by you in
connection with any subsequent employment (or self-employment) during the
24-month period following your termination.

(viii) When you attain
age 55, if you are eligible to participate in the Company’s retiree health and
life insurance plans, you will receive monthly payments from the Company to
reimburse you for your cost to participate in those plans, grossed up for your
taxes.  If you are not eligible to
participate in the Company’s retiree health and life insurance plans, you will
instead receive cash payments equivalent on an after-tax basis to the value of
the retiree health and life insurance benefits you would have received under
the Company’s retiree health and life insurance plans (providing benefits no
less than those provided in the year in which you first entered into a Change
in Control Agreement with the Company) had you qualified for full retiree
health and life insurance benefits under the Company’s retiree health and life
insurance plans, with such payments to be made by the Company to you on a
monthly basis (it being understood that the Company payments to you
attributable to the health and life insurance benefits will be equal on an
after-tax basis to the monthly premium cost to you to purchase such benefits
separately, which shall not exceed the highest risk premium charged by a
carrier having an investment grade or better credit rating).  Notwithstanding the foregoing, the benefits
described in this Section 3(b)(viii) shall constitute secondary coverage with
respect to any health or life insurance benefits actually received by you in
connection with any subsequent employment (or self-employment) or otherwise
following your attainment of age 55.

(c) Excise Tax.  In the event you become entitled to any
amounts payable in connection with a Change in Control (whether or not such
amounts are payable pursuant to this Agreement) (the “Severance Payments”), if
any of such

 5
 

Severance Payments are subject to the tax (the “Excise
Tax”) imposed by Section 4999 of the Code (or any similar federal, state or
local tax that may hereafter be imposed), the Company shall pay to you at the
time specified herein an additional amount (the “Gross-Up Payment”) such that
the net amount retained by you, after deduction of any Excise Tax on the Total
Payments (as hereinafter defined) and any federal, state and local income tax
and Excise Tax upon the payment provided for by this Section 3(c), shall be
equal to the Total Payments. For purposes of determining whether any of the
Severance Payments will be subject to the Excise Tax and the amount of such
Excise Tax: (i) any other payments or benefits received or to be received by
you in connection with a Change in Control or your termination of employment
(whether pursuant to the terms of this Agreement or any other plan, arrangement
or agreement with the Company, any Person whose actions result in a Change in
Control or any Person affiliated with the Company or such Person) (which,
together with the Severance Payments, constitute the “Total Payments”) shall be
treated as “parachute payments” within the meaning of Section 280G(b)(2) of the
Code, and all “excess parachute payments” within the meaning of Section
280G(b)(1) of the Code shall be treated as subject to the Excise Tax, unless in
the opinion of nationally-recognized tax counsel selected by you such other
payments or benefits (in whole or in part) do not constitute parachute
payments, or such excess parachute payments (in whole or in part) represent
reasonable compensation for services actually rendered within the meaning of
Section 280G(b)(4) of the Code in excess of the base amount within the meaning
of Section 280G(b)(3) of the Code, or are otherwise not subject to the Excise
Tax; (ii) the amount of the Total Payments which shall be treated as subject to
the Excise Tax shall be equal to the lesser of (A) the total amount of the
Total Payments and (B) the amount of excess parachute payments within the
meaning of Section 280G(b)(1) of the Code (after applying Section 3(c)(i)
hereof); and (iii) the value of any non-cash benefits or any deferred payments
or benefit shall be determined by a nationally-recognized accounting firm
selected by you in accordance with the principles of Sections 280G(d)(3) and
(4) of the Code.  For purposes of
determining the amount of the Gross-Up Payment, you shall be deemed to pay
federal income taxes at the highest marginal rate of federal income taxation in
the calendar year in which the Gross-Up Payment is to be made and state and
local income taxes at the highest marginal rate of taxation in the state and
locality of your residence on the Date of Termination, net of the maximum
reduction in federal income taxes which could be obtained from deduction of
such state and local taxes.  In the event
that the Excise Tax is subsequently determined to be less than the amount taken
into account hereunder at the time of termination of your employment, you shall
repay to the Company within ten days after the time that the amount of such
reduction in Excise Tax is finally determined the portion of the Gross-Up
Payment attributable to such reduction (plus the portion of the Gross-Up
Payment attributable to the Excise Tax and federal and state and local income
tax imposed on the Gross-Up Payment being repaid by you if such repayment
results in a reduction in Excise Tax and/or federal and state and local income
tax deduction) plus interest on the amount of such repayment at the rate
provided in Section 1274(b)(2)(B) of the Code. 
In the event that the Excise Tax is determined to exceed the amount
taken into account hereunder at the time of the termination of your employment
(including by reason of any payment the existence or amount of which cannot be
determined at the time of the Gross-Up Payment), the Company shall make an
additional gross-up payment in respect of such excess ten days after the time
that the amount of such excess is finally determined.  The payments provided for in this Section
3(c) shall be made on the fifteenth day following your Date of Termination; provided,
however, that if the amount of such payments cannot be finally determined
on or before such day, the Company shall pay you on such day an estimate, as
determined in good faith by the Company, of the minimum amount of such payments
and shall pay the remainder of such payments (together with interest at the
rate provided in Section 1274(b)(2)(B) of the Code) as soon as

 6
 

administratively practicable in compliance with
Section 409A of the Code and the proposed and final Treasury Regulations
thereunder, as the same may be amended from time to time (the “Regulations”)
but in no event later than the thirtieth day after your Date of Termination subject,
however, to any delay in the payment date as a result of Section 3(d) of this
Agreement (relating to the six-month delay in payment of certain benefits to
Specified Employees as required by Section 409A of the Code).  In the event that the amount of the estimated
payments exceeds the amount subsequently determined to have been due, such
excess shall constitute a loan by the Company to you, payable on the fifteenth
day after the demand by the Company (together with interest at the rate
provided in Section 1274(b)(2)(B) of the Code).

(d) Delay in Payment
to Specified Employees.  Anything in
this Agreement to the contrary notwithstanding, payments to be made under this
Agreement upon your termination of employment which are subject to Section 409A
of the Code shall be delayed for six months following such termination of
employment if you are a “Specified Employee” as defined in Section 3(f) on your
Date of Termination.  Any payment due
within such six-month period shall be delayed to the end of such six-month
period. The Company will adjust the payment to reflect the deferred payment
date by multiplying the payment by the product of the six-month CMT Treasury
Bill annualized yield rate as published by the U.S. Treasury for the date on
which such payment would have been made but for the delay multiplied by a
fraction, the numerator of which is the number of days by which such payment
was delayed and the denominator of which is 365. The Company will pay the
adjusted payment at the beginning of the seventh month following your Date of
Termination. Notwithstanding the foregoing, if calculation of the amounts
payable by any payment date specified in this Section 3(d) is not
administratively practicable due to events beyond your control (or the control
of your beneficiary or estate) and for reasons that are commercially
reasonable, payment will be made as soon as administratively practicable in
compliance with Section 409A of the Code and the Regulations.  In the event of your death during such
six-month period, payment will be made in the payroll period next following the
payroll period in which your death occurs.

(e) Notice.  During the Protected Period, any purported
termination of your employment by the Company or by you shall be communicated
by written Notice of Termination to the other party hereto.

(f) Certain
Definitions.  Except as otherwise
indicated in this Agreement, all definitions in this Section 3(f) shall be
applicable during the Protected Period only.

(i) Cause.  “Cause” shall mean termination on account of
(A) the willful and continued failure by you to substantially perform your
duties with the Company (other than any such failure resulting from your
incapacity due to physical or mental illness or Disability or any failure after
the issuance of a Notice of Termination by you for Good Reason) which failure
is demonstrably and materially damaging to the financial condition or
reputation of the Company and/or its subsidiaries, and which failure continues
more than 48 hours after a written demand for substantial performance is
delivered to you by the Board, which demand specifically identifies the manner
in which the Board believes that you have not substantially performed your
duties and the demonstrable and material damage caused thereby or (B) the willful
engaging by you in conduct which is demonstrably and materially injurious to
the Company, monetarily or otherwise.  No
act, or failure to act, on your part shall be deemed “willful” unless done, or
omitted to be done, by you not in good faith and without reasonable belief that
your action or omission was

 7
 

in the best interest of the Company.  Notwithstanding the foregoing, you shall not
be deemed to have been terminated for Cause unless and until there shall have
been delivered to you a copy of the resolution duly adopted by the affirmative
vote of not less than three-quarters (3/4) of the entire membership of the
Board at a meeting of the Board (after reasonable notice to you and an
opportunity for you, together with your counsel, to be heard before the Board)
finding that, in the good faith opinion of the Board, you were guilty of
conduct set forth above in this Section 3(f)(i) and specifying the particulars
thereof in detail.

(ii) Date of
Termination.  “Date of Termination”
shall mean (A) if your employment is terminated for Disability, 30 days after
Notice of Termination is given (provided that you shall not have returned to
the full-time performance of your duties during such 30-day period) or (B) if
your employment is terminated for any other reason, the date specified in the
Notice of Termination (which, in the case of a termination for Cause, shall not
be less than 30 days from the date such Notice of Termination is given and, in
the case of a termination for Good Reason, shall not be less than 15 nor more
than 60 days from the date such Notice of Termination is given).

(iii) Disability.  “Disability” shall mean your absence from the
full-time performance of your duties with the Company for six consecutive
months as a result of your incapacity due to physical or mental illness or
disability, and within 30 days after written Notice of Termination is
thereafter given you shall not have returned to the full-time performance of
your duties.

(iv) Good Reason.  “Good Reason” shall mean, without your express
written consent, the occurrence upon or after a Change in Control of any of the
following circumstances unless, in the case of Sections 3(f)(iv)(A), (D), (F)
or (G) hereof, such circumstances are fully corrected prior to the Date of
Termination specified in the Notice of Termination given in respect thereof:

(A) the assignment to you
of any duties inconsistent with the position in the Company that you held
immediately prior to the Change in Control, or an adverse alteration in the
nature or status of your responsibilities or the conditions of your employment
from those in effect immediately prior to such Change in Control;

(B) a reduction by the
Company in your annual base salary, any target bonus or perquisites as in
effect immediately prior to the Change in Control or as the same may be
increased from time to time except for across-the-board perquisite reductions
similarly affecting all senior executives of the Company and all senior
executives of any Person in control of the Company;

(C) the relocation of the
principle place of your employment to a location more than 50 miles from the
location of such place of employment on the date of this Agreement except for
required travel on the Company’s business to an extent substantially consistent
with your business travel obligations prior to the Change in Control;

(D) the failure by the
Company to pay to you any portion of your compensation or to pay to you any
portion of an installment of deferred compensation under any deferred
compensation program of the Company within seven days of the date such
compensation is due;

(E) the failure by the
Company to continue in effect any material compensation or benefit plan in
which you participated immediately prior to

 8
 

the Change in Control, unless an equitable arrangement
(embodied in an ongoing substitute or alternative plan) has been made with
respect to such plan, or the failure by the Company to continue your
participation therein (or in such substitute or alternative plan) on a basis
not materially less favorable, both in terms of the amounts of benefits
provided and the level of your participation relative to other participants, as
existed at the time of the Change in Control;

(F) the failure of the
Company to obtain a satisfactory agreement from any successor to assume and
agree to perform this Agreement, as contemplated in Section 7 hereof; or

(G) any purported
termination of your employment that is not effected pursuant to a Notice of
Termination satisfying the requirements of Section 3(f)(v) (and, if applicable,
the requirements of Section 3(f)(i) hereof), which purported termination shall
not be effective for purposes of this Agreement.

(v) Notice of
Termination.  “Notice of Termination”
shall mean notice indicating the specific termination provision in this Agreement
relied upon and setting forth in reasonable detail the facts and circumstances
claimed to provide a basis for termination of your employment under the
provision so indicated.

(vi) Specified
Employee. “Specified Employee” shall mean an employee of the Company who
satisfies the requirements for being designated a “key employee” under Section
416(i)(1)(A)(i), (ii) or (iii) of the Code without regard to Section 416(i)(5)
of the Code at any time during a calendar year, in which case such employee
shall be considered a Specified Employee for the twelve-month period beginning
on the first day of the fourth month immediately following the end of such
calendar year. Notwithstanding the foregoing, all employees who are nonresident
aliens during an entire calendar year are excluded for purposes of determining
which employees meet the requirements of Section 416(i)(1)(A)(i), (ii) or (iii)
of the Code without regard to Section 416(i)(5) of the Code for such calendar
year. The term “nonresident alien” as used herein shall have the meaning set
forth in Regulations Section 1.409A-1(j). 
In the event of any corporate spinoff or merger, the determination of
which employees meet the requirements of Section 416(i)(1)(A)(i), (ii) or (iii)
of the Code without regard to Section 416(i)(5) of the Code for any calendar
year shall be determined in accordance with Regulations Section 1.409A-1(i)(2).

4. Mitigation.  Except as provided in Sections 3(b)(vii) and
(viii) and Section 6 hereof, you shall not be required to mitigate the amount
of any payment provided for under this Agreement by seeking other employment or
otherwise, nor shall the amount of any payment or benefit provided for under
this Agreement be reduced by any compensation earned by you as the result of
employment by another employer, by retirement benefits, by offset against any
amount claimed to be owed by you to the Company, or otherwise.

5.  Release of Employment Claims.  You agree, as a condition to your receipt of
the compensation and benefits provided for under this Agreement, that you will
execute a general release agreement, in substantially the form set forth as
Attachment A to this Agreement, releasing any and all claims arising out of
your employment other than: (a) the enforcement of this Agreement; (b) with respect
to vested rights or rights provided for under any benefit plan or arrangement
of the Company; or (c) rights to indemnification under any agreement, law,
Company organizational document or policy, or otherwise.

 9
 

6.  Forfeiture.  Except as otherwise provided in Section
3(b)(v) of this Agreement, if you willfully and materially fail to comply with
the terms of your Restrictive Covenant Agreement with the Company or if you
willfully and materially fail to comply with Section 2(c) or Section 5 of this
Agreement, all compensation and benefits provided for under this Agreement
shall be immediately forfeited. Notwithstanding the foregoing, you shall not
forfeit any compensation or benefits provided for under this Agreement unless
and until there shall have been delivered to you, within six months after the
Board (a) had knowledge of conduct or an event allegedly constituting grounds
for such forfeiture and (b) had reason to believe that such conduct or event
could be grounds for such forfeiture, a copy of a resolution duly adopted by a
majority affirmative vote of the membership of the Board at a meeting of the
Board called and held for such purpose (after giving you reasonable notice
specifying the nature of the grounds for such forfeiture and not less than 30 days
to correct the acts or omissions complained of, if correctable, and affording
you the opportunity, together with your counsel, to be heard before the Board)
finding that, in the good faith opinion of the Board, you have engaged and
continue to engage in conduct which constitutes grounds for forfeiture of your
compensation and benefits under this Agreement; provided, however, that in the
event that you shall have already received any compensation or benefits under
this Agreement before the Board makes the determination described in this
sentence, you shall immediately reimburse the Company for such compensation
and/or benefits following such determination by the Board. The forfeiture of
any compensation or benefits provided for under this Agreement by reason of
this Section 6 shall apply to such compensation and benefits notwithstanding
any other term or provision of this Agreement or any other agreement or plan.

7. Successors; Binding
Agreement.

(a) The Company shall
require any successor (whether direct or indirect, by purchase, merger,
consolidation or otherwise) to all or substantially all of the business and/or
assets of the Company to expressly assume and agree to perform this Agreement
in the same manner and to the same extent that the Company would be required to
perform it if no such succession had taken place.  As used in this Agreement, “Company” shall
mean the Company as hereinbefore defined and any successor to its business
and/or assets as aforesaid which assumes and agrees to perform this Agreement
by operation of law, or otherwise.

(b) This Agreement shall
inure to the benefit of and be enforceable by you and your personal or legal
representatives, executors, administrators, successors, heirs, distributees,
devisees and legatees.  In the event of
your death, all amounts otherwise payable to you hereunder shall, unless
otherwise provided herein, be paid in accordance with the terms of this
Agreement to your devisee, legatee or other designee or, if there is no such
designee, to your estate.

8. Notice.  Notices and all other communications provided
for in this Agreement shall be in writing and shall be deemed to have been duly
given when (a) personally delivered or (b) mailed by United States certified or
registered mail, return receipt requested, postage prepaid, addressed to the
respective addresses set forth on the first page of this Agreement; provided
that all notice to the Company shall be directed to the attention of the
Board with a copy to the General Counsel of the Company, or to such other
address as either party may have furnished to the other in writing in
accordance herewith, except that notice of change of address shall be effective
only upon receipt.

9. Miscellaneous.  No provision of this Agreement may be
modified, waived or discharged unless such waiver, modification or discharge is
agreed to in writing and

 10
 

signed by you and such officer as may be designated by
the Board.  No waiver by either party
hereto at any time of any breach by the other party hereto of, or compliance
with, any condition or provision of this Agreement to be performed by such
other party shall be deemed a waiver of similar or dissimilar provisions or
conditions at the time or at any prior or subsequent time.  Any payments provided for hereunder shall be
paid net of any applicable withholding required under federal, state or local
law.  The obligations of the Company
under this Agreement shall survive the expiration of this Agreement to the
extent necessary to give effect to this Agreement.

10. Validity.  The invalidity or unenforceability of any
provision of this Agreement shall not affect the validity or enforceability of
any other provision of this Agreement, which shall remain in full force and
effect.

11. Counterparts.  This Agreement may be executed in counterparts,
each of which shall be deemed to be an original but all of which together will
constitute one and the same instrument.

12. Entire Agreement.  This Agreement sets forth the entire
agreement of the parties hereto in respect of the subject matter contained
herein and during the term of this Agreement supersedes the provisions of all
prior agreements, promises, covenants, arrangements, communications,
representations or warranties, whether oral or written, by any officer,
employee or representative of any party hereof with respect to the subject
matter contained herein.  No agreements
or representations, oral or otherwise, express or implied, with respect to the
subject matter hereof have been made by either party which are not expressly
set forth in this Agreement. 
Notwithstanding anything to the contrary in this Agreement, the
procedural provisions of this Agreement shall apply to all benefits payable as
a result of a Change in Control (or other change in control) under any employee
benefit plan, agreement, program, policy or arrangement of the Company.  The foregoing notwithstanding, in the event
of any conflict or ambiguity between this Agreement and any employment
agreement executed by you and the Company, the provisions of such employment
agreement shall govern; but no payment or benefit under this Agreement shall be
made or extended which duplicates any payment or benefit under any such
employment agreement.

13.  Governing Law.    This Agreement is
governed by and is to be construed, administered, and enforced in accordance
with the laws of the State of Connecticut, without regard to conflicts of law
principles. If under the governing law, any portion of this Agreement is at any
time deemed to be in conflict with any applicable statute, rule, regulation,
ordinance, or other principle of law, such portion shall be deemed to be
modified or altered to the extent necessary to conform thereto or, if that is
not possible, to be omitted from this Agreement. The invalidity of any such
portion shall not affect the force, effect, and validity of the remaining
portion hereof. Anything in this Agreement to the contrary notwithstanding, the
terms of this Agreement shall be interpreted and applied in a manner consistent
with the requirements of Section 409A of the Code and the Regulations
thereunder and the Company shall have no right to accelerate or make any
payment under this Agreement except to the extent permitted under Section 409A
of the Code.  The Company shall have no
obligation, however, to reimburse you for any tax penalty or interest payable
or provide a gross-up payment in connection with any tax liability you may
incur under Section 409A of the Code except that this provision shall not apply
in the event of the Company’s negligence or willful disregard in interpreting
the application of Section 409A of the Code to this Agreement which negligence
or willful disregard causes you to become subject to a tax penalty or interest
payable under Section 409A of the Code nor shall

 11
 

this provision be interpreted to limit any gross-up
payable to you under Section 3(c) of this Agreement.

14.    Reimbursement of
Expenses in Enforcing Rights.    All
reasonable costs and expenses (including fees and disbursements of counsel)
incurred by you in seeking to interpret this Agreement or enforce rights
pursuant to this Agreement shall be paid on behalf of or reimbursed to you
promptly by the Company, whether or not you are successful in asserting such
rights; provided, however, that no reimbursement shall be made of such expenses
relating to any unsuccessful assertion of rights if and to the extent that your
assertion of such rights was in bad faith or frivolous, as determined by
arbitrators in accordance with Section 15 or a court having jurisdiction
over the matter.  Any such payment or
reimbursement shall be made in a lump sum in the month next following the month
in which such costs and expenses are incurred subject to your submission of
receipts for such expenses.

15.    Arbitration.    Any dispute or
controversy arising under or in connection with this Agreement shall be settled
exclusively by arbitration in Fairfield, Connecticut by three arbitrators in
accordance with the National Rules for the Resolution of Employment
Disputes of the American Arbitration Association in effect at the time of
submission to arbitration. Judgment may be entered on the arbitrators’ award in
any court having jurisdiction. For purposes of entering any judgment upon an
award rendered by the arbitrators, the Company and you hereby consent to the jurisdiction
of any or all of the following courts: (a) the United States District
Court for the District of Connecticut, (b) any of the courts of the State
of Connecticut, or (c) any other court having jurisdiction. The Company
and you further agree that any service of process or notice requirements in any
such proceeding shall be satisfied if the rules of such court relating
thereto have been substantially satisfied. The Company and you hereby waive, to
the fullest extent permitted by applicable law, any objection which it may now
or hereafter have to such jurisdiction and any defense of inconvenient forum.
The Company and you hereby agree that a judgment upon an award rendered by the
arbitrators may be enforced in other jurisdictions by suit on the judgment or
in any other manner provided by law. Subject to Section 14, the Company shall
bear all costs and expenses arising in connection with any arbitration
proceeding pursuant to this Section 15 and shall pay such costs and
expenses in the tax year in which incurred. Notwithstanding any provision in
this Section 15, you shall be paid during the pendency of any dispute or
controversy arising under or in connection with this Agreement.

16.    Interest on Unpaid
Amounts.    Any
amount which has become payable pursuant to the terms of this Agreement or any
decision by arbitrators or judgment by a court of law pursuant to
Section 15 but which has not been timely paid shall bear interest at the
prime rate in effect at the time such amount first becomes payable, as quoted
by the Company’s principal bank, except as otherwise provided in Section 3(d)
of this Agreement (concerning interest payable with respect to delayed payments
under Section 409A of the Code).

 12
 

If this letter sets forth our agreement on the subject
matter hereof, kindly sign and return to the Company the enclosed copy of this
letter, which will then constitute our agreement on this subject.

	
  

  	
   

  	
  IMS HEALTH INCORPORATED

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  Chairman and Chief Executive Officer

  

 

	
  Agreed to this
                                       
  day

  	
   

  
	
   

  	
   

  
	
  of
                                                       ,
  2007.

  	
   

  
	
   

  

 

 13
 

ATTACHMENT
A

RELEASE

We advise you to consult an attorney before you sign
this Release.  You have until the date
which is seven (7) days after the Release is signed and returned to IMS Health
Incorporated to change your mind and revoke your Release.  Your Release shall not become effective or
enforceable until after that date.

In consideration for the benefits provided under your
Change-in-Control Agreement with IMS Health Incorporated (the “Agreement”), by
your signature below, you, for yourself and on behalf of your heirs, executors,
agents, representatives, successors and assigns, hereby release and forever
discharge IMS Health Incorporated, its past and present parent corporations,
subsidiaries, divisions, subdivisions, affiliates and related companies
(collectively, the “Company”) and the Company’s past, present and future agents,
directors, officers, employees, representatives, assigns, stockholders,
attorneys, agents, insurers, employee benefit programs (and the trustees,
administrators, fiduciaries and insurers of such programs), and any other
persons acting by, through, under or in concert with any of the persons or
entities listed herein, and their successors (hereinafter “those associated
with the Company”) and with respect to any and all claims, demands, actions and
liabilities, whether in law or equity, which you may have against the Company
or those associated with the Company of whatever kind, including but not
limited to those arising out of your employment with the Company or the
termination of that employment.  You
agree that this Release covers, but is not limited to, claims arising under the
Age Discrimination in Employment Act of 1967, 29 U.S.C. § 621 et seq., Title
VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., the Americans
with Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., the Fair Labor Standards
Act, 29 U.S.C. § 201 et seq., the Employee Retirement Income Security Act of
1974, 29 U.S.C. § 1001 et seq., the Family and Medical Leave Act of 1993 and
any local, state or federal law, regulation or order providing workers’
compensation benefits, restricting an employer’s right to terminate employees
or otherwise regulating employment, enforcing express or implied employment
contracts or requiring an employer to deal with employees fairly or in good
faith, or dealing with discrimination in employment on the basis of sex, race,
color, national origin, veteran status, marital status, religion, disability,
handicap, or age.  You also agree that
this Release includes claims based on wrongful termination of employment,
breach of contract (express or implied), tort, or claims otherwise related to
your employment or termination of employment with the Company and any claim for
attorneys’ fees, expenses or costs of litigation.

This Release covers all claims based on any facts or
events, whether known or unknown by you, that occurred on or before the date of
this Release. You expressly waive all rights you might have under any law that
is intended to protect you from waiving unknown claims and by your signature
below indicate your understanding of the significance of doing so. Examples of
released claims include, but are not limited to:  (a) claims that in any way relate to your
employment with the Company, or the termination of that employment, such as
claims for compensation, bonuses, commissions, lost wages, or unused accrued
vacation or sick pay (other than under your Agreement); (b) claims that in any
way relate to the design or administration of any employee benefit program; (c)
claims that you have irrevocable or vested rights to severance or similar benefits
(other than under your Agreement) or to post-employment health or group
insurance benefits (other than under your Agreement); (d) any claim, such as a
benefit claim, that was explicitly or implicitly denied before you signed this
Release; (e) any claim you might have for extra benefits as a consequence of
payments you receive because of signing this Release; or (f) any claim to
attorneys’ fees or other indemnities. 
Except to enforce your Agreement or this Release, you agree that you
will never commence, prosecute, or cause to be commenced or

 14
 

prosecuted any lawsuit or proceeding of any kind
against the Company or those associated with the Company in any forum and agree
to withdraw with prejudice all complaints or charges, if any, that you have
filed against the Company or those associated with the Company.

Anything in this Release to the contrary
notwithstanding, this Release does not include a release of:  (i) any of your rights under the
Agreement;  (ii) any rights you may have
to indemnification under any agreement, law, Company organizational document or
policy, or otherwise; (iii) any rights you may have to benefits under the
Company’s benefit plans except as otherwise provided in your Agreement or
claims specifically identified in this Release; (iv) any rights or claims under
the Age Discrimination in Employment Act or any other law that arise after you
sign this Release; or (iii) your right to enforce this Release or any of the
foregoing items described in this paragraph.

By signing this Release, you further agree as follows:

i.              You
have read this Release carefully and fully understand its terms;

ii.             You
have had at least twenty-one (21) days to consider the terms of the Release;

iii.            You
have seven (7) days from the date you sign this Release to revoke it by written
notification to the Company.  After this
seven (7)-day period, this Release is final and binding and may not be revoked;

iv.            You
have been advised to seek legal counsel and have had an opportunity to do so;

v.             You
would not otherwise be entitled to the benefits provided under your Agreement
had you not agreed to execute this Release; and

vi.            Your
agreement to the terms set forth above is voluntary.

(The remainder of this page was intentionally left blank)

 15

TIER-4

CHANGE-IN-CONTROL AGREEMENT

FOR CERTAIN EXECUTIVES

OF IMS HEALTH
INCORPORATED

[Date]

PERSONAL AND CONFIDENTIAL

[Name and Title]

IMS Health Incorporated

Dear [               ]:

IMS Health Incorporated
(the “Company”) considers it essential to the best interests of its
stockholders to foster the continued employment of key management
personnel.  In this connection, the Board
of Directors of the Company (the “Board”) recognizes that the possibility of a
change in ownership or control of the Company may result in the departure or
distraction of such personnel to the detriment of the Company and its
stockholders.  As you are a skilled and
dedicated executive with important management responsibilities and talents, the
Company believes that its best interests will be served if you are encouraged
to remain with the Company.

The Company has
determined that your ability to perform your responsibilities and utilize your
talents for the benefit of the Company, and the Company’s ability to retain you
as an employee, will be significantly enhanced if you are provided with fair
and reasonable protection from the risks of a change in ownership or control of
the Company.  Accordingly, in order to
induce you to remain in the employ of the Company, you and the Company agree as
follows:

1. Term of Agreement.

(a) Generally.  Except as provided in Section 1(b) hereof,
(i) this Agreement shall be effective as of January 1, 2007 and shall continue
in effect through December 31, 2008, and (ii) commencing on January 1, 2009,
and each January 1 thereafter, this Agreement shall be automatically extended
for one additional year unless, not later than November 30th of the preceding
year, either party to this Agreement gives notice to the other that the
Agreement shall not be extended under this Section 1(a); provided, however,
that no such notice by the Company shall be effective if a Change in Control or
Potential Change in Control (both as defined herein) shall have occurred prior
to the date of such notice.

(b) Upon a Change in
Control.  If a Change in Control
shall have occurred at any time during the period in which this Agreement is
effective, this Agreement shall continue in effect for (i) the remainder of the
month in which the Change in Control occurred and (ii) a term of 24 months
beyond the month in which such Change in Control occurred (such entire period
hereinafter referred to as the “Protected Period”).

2. Change in Control;
Potential Change in Control.

(a) A “Change in Control”
shall be deemed to have occurred if, during the term of this Agreement:

(i) any “Person,” as such
term is used for purposes of Section 13(d) or 14(d) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”) (other than the Company, any
trustee or other fiduciary holding securities under an employee benefit plan of
the Company, or any company owned, directly or indirectly, by the stockholders
of the Company in substantially the same proportions as their ownership of
stock of the Company), becomes the “Beneficial Owner” (as defined in Rule 13d-3
under the Exchange Act), directly or indirectly, of securities of the Company
representing 20% or more of the combined voting power of the Company’s
then-outstanding securities;

(ii) during any period of
twenty-four months (not including any period prior to the effectiveness of this
Agreement), individuals who at the beginning of such period constitute the
Board, and any new director (other than (A) a director nominated by a Person
who has entered into an agreement with the Company to effect a transaction
described in Sections (2)(a)(i), (iii) or (iv) hereof, (B) a director nominated
by any Person (including the Company) who publicly announces an intention to
take or to consider taking actions (including, but not limited to, an actual or
threatened proxy contest) which if consummated would constitute a Change in
Control or (C) a director nominated by any Person who is the Beneficial Owner,
directly or indirectly, of securities of the Company representing 10% or more
of the combined voting power of the Company’s securities) whose election by the
Board or nomination for election by the Company’s stockholders was approved in
advance by a vote of at least two-thirds (2/3) of the directors then still in
office who either were directors at the beginning of the period or whose
election or nomination for election was previously so approved, cease for any
reason to constitute at least a majority thereof;

(iii) any transaction (or
series of transactions) is consummated under which the Company is merged or
consolidated with any other company, other than a merger or consolidation (A)
which would result in the voting securities of the Company outstanding
immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving
entity) more than 66 2/3% of the combined voting power of the voting securities
of the Company or such surviving entity outstanding immediately after such
merger or consolidation and (B) after which no Person holds 20% or more of the
combined voting power of the then-outstanding securities of the Company or such
surviving entity;

(iv) a sale or
disposition by the Company of all or substantially all of the Company’s assets
is consummated or the stockholders of the Company approve a plan of complete
liquidation of the Company; or

(v) the Board adopts a
resolution to the effect that, for purposes of this Agreement, a Change in
Control has occurred.

(b) A “Potential Change
in Control” shall be deemed to have occurred if:

(i) the Company enters
into an agreement, the consummation of which would result in the occurrence of
a Change in Control;

 2
 

(ii) any Person
(including the Company) publicly announces an intention to take or to consider
taking actions which if consummated would constitute a Change in Control; or

(iii) the Board adopts a
resolution to the effect that, for purposes of this Agreement, a Potential
Change in Control has occurred.

(c) Employee Covenants.  You agree that, subject to the terms and
conditions of this Agreement, in the event of a Potential Change in Control,
you will remain in the employ of the Company until the earliest of (i) a date
which is 180 days from the occurrence of such Potential Change in Control, (ii)
the termination of your employment by reason of Disability (as defined herein)
or (iii) the date on which you first become entitled under this Agreement to
receive the benefits provided in Section 3(b) hereof.

(d) Company Covenant
Regarding Potential Change in Control or Change in Control.  In the event of a Potential Change in Control
or a Change in Control, the Company shall, not later than 15 days thereafter,
have established one or more rabbi trusts and shall deposit therein cash in an
amount sufficient to provide for full payment of all potential obligations of
the Company that would arise assuming consummation of a Change in Control and a
subsequent termination of your employment under Section 3(b).  Such rabbi trust(s) shall be irrevocable and
shall provide that the Company may not, directly or indirectly, use or recover
any assets of the trust(s) until such time as all obligations which potentially
could arise hereunder have been settled and paid in full or otherwise
extinguished, subject only to the claims of creditors of the Company in the event
of insolvency or bankruptcy of the Company; provided, however, that if no
Change in Control has occurred within two years after such Potential Change in
Control, such rabbi trust(s) shall at the end of such two-year period become
revocable and may thereafter be revoked by the Company.

3. Termination.

(a) Termination by the
Company for Cause, by You Without Good Reason, or by Reason of Death or
Disability.  If during the Protected
Period your employment by the Company is terminated by the Company for Cause,
by you without Good Reason, or because of your death or Disability, the Company
shall be relieved of its obligation to make any payments to you other than (i)
its payment of amounts otherwise accrued and owing but not yet paid and (ii)
any amounts payable under then-existing employee benefit programs at the time
such amounts are due.

(b) Termination by the
Company Without Cause or by You for Good Reason.  If during the Protected Period your
employment by the Company is terminated by the Company without Cause or by you
for Good Reason, you shall be entitled to the compensation and benefits
described in this Section 3(b).  If your
employment by the Company is terminated prior to a Change in Control at the
request of a Person engaging in a transaction or series of transactions that
would result in a Change in Control, the Protected Period shall commence upon
the subsequent occurrence of a Change in Control, your actual termination shall
be deemed a termination occurring during the Protected Period and covered by
this Section 3(b), your Date of Termination shall be deemed to have occurred
immediately following the Change in Control, and Notice of Termination shall be
deemed to have been given by the Company immediately prior to your actual
termination.  Your continued employment
shall not constitute consent to, or a waiver 

 3
 

of rights with respect to, any circumstances
constituting Good Reason hereunder.  The
compensation and benefits provided under this Section 3(b) are as follows:

(i) The Company shall pay
you your full base salary through the Date of Termination at the rate in effect
at the time Notice of Termination is given, on the fifth day following the Date
of Termination, and you shall receive all other amounts to which you are
entitled under any compensation or benefit plan of the Company, at the time
such payments are due in accordance with the terms of such compensation or
benefit plan.

(ii) In the payroll
period next following the payroll period in which your Date of Termination
occurs, the Company shall pay you, in lieu of any further salary, bonus or
severance payments for periods subsequent to the Date of Termination, a lump
sum amount in cash equal to one times the sum of:

(A) the greater of (I)
your annual base salary in effect immediately prior to the Change in Control of
the Company or (II) your annual base salary in effect at the time Notice of
Termination is given; and

(B) the greater of (I)
your annual target bonus for the year in which the Change in Control occurs or,
(II) if no such target bonus has yet been determined for such year, the annual
bonus actually earned by you in the year immediately preceding the year in
which the Change in Control occurs.

(iii) In the payroll
period next following the payroll period in which your Date of Termination
occurs, the Company shall pay to you, in lieu of amounts which may otherwise be
payable to you under the Executive Annual Incentive Plan or any other bonus
plan (the “Bonus Plan”), an amount in cash equal to (A) that portion of your
annual target bonus payable in cash for the year in which the Change in Control
occurs, multiplied by a fraction, (I) the numerator of which equals the number
of full or partial days in such annual performance period during which you were
employed by the Company and (II) the denominator of which is 365, and (B) the
entire target bonus opportunity with respect to each performance period in
progress for any bonus payable to you in stock under all Bonus Plans in effect
at the time of termination.

(iv) The Company shall
provide you with a cash allowance for outplacement and job search activities
(including, but not limited to, office and secretarial expenses) in the amount
of 20% of your annual base salary and annual target bonus taken into account
under Section 3(b)(ii) hereof, provided that (A) such cash allowance
shall not exceed $100,000 and (B) such cash allowance shall apply only to those
costs or obligations that are incurred by you during the 12-month period
following your termination of employment. 
Payments of such cash allowance shall be made on the fifteenth day
following the submission of each receipt to the Company evidencing costs or
obligations incurred by you in connection with outplacement and job search
activities.

(v)  Notwithstanding the provisions of your Restrictive
Covenant Agreement with the Company, your agreement set forth in such
Restrictive Covenant Agreement not to compete with the Company for one year
after your termination of employment shall not apply; however, the other
provisions of your Restrictive Covenant Agreement shall remain in full force
and effect, including without limitation, the non-solicitation, non-disclosure,
confidentiality and non-disparagement covenants set forth therein.

 4
 

(vi)  If you are an expatriate, you will be
repatriated, at the Company’s expense, to your home country or to any other
country you choose provided that the Company’s cost for your repatriation will
not exceed the cost the Company would have incurred had it repatriated you to
your home country.  Your repatriation allowances
and benefits will be as described in the Company’s Long-Term Assignment Policy
but there will be no claw-back of any relocation costs by reason of the early
termination of your assignment.

(vii) During the 12-month
period following your termination of employment, you will receive fully
subsidized COBRA coverage (grossed up for your taxes) under the Company’s
health plan for so long as it is available and thereafter you will be paid cash
payments equivalent on an after-tax basis to the value of the health plan
benefits you would have received under the Company’s health plan had you
continued to be employed during such 12-month period, with such payments to be
made by the Company to you on a monthly basis (it being understood that the
Company payments to you attributable to the health plan benefits will be equal
on an after-tax basis to the monthly premium cost to you to purchase such
health plan benefits separately, which shall not exceed the highest risk
premium charged by a carrier having an investment grade or better credit
rating).  You will also receive during
such 12-month period cash payments equivalent on an after-tax basis to the
value of the life insurance benefits you would have received under the
Company’s life insurance plan had you continued to be employed during such
12-month period, with such payments to be made by the Company to you on a
monthly basis (it being understood that the Company payments to you
attributable to the life insurance plan benefits will be equal on an after-tax
basis to the monthly premium cost to you to purchase such life insurance plan
benefits separately, which shall not exceed the highest risk premium charged by
a carrier having an investment grade or better credit rating).  Notwithstanding the foregoing, the benefits
described in this Section 3(b)(vii) shall constitute secondary coverage with
respect to any health or life insurance benefits actually received by you in
connection with any subsequent employment (or self-employment) during the
12-month period following your termination.

(viii) When you attain
age 55, if you are eligible to participate in the Company’s retiree health and
life insurance plans, you will receive monthly payments from the Company to
reimburse you for your cost to participate in those plans, grossed up for your
taxes.  If you are not eligible to
participate in the Company’s retiree health and life insurance plans, you will
instead receive cash payments equivalent on an after-tax basis to the value of
the retiree health and life insurance benefits you would have received under
the Company’s retiree health and life insurance plans (providing benefits no
less than those provided in the year in which you first entered into a Change
in Control Agreement with the Company) had you qualified for full retiree
health and life insurance benefits under the Company’s retiree health and life
insurance plans, with such payments to be made by the Company to you on a
monthly basis (it being understood that the Company payments to you
attributable to the health and life insurance benefits will be equal on an
after-tax basis to the monthly premium cost to you to purchase such benefits
separately, which shall not exceed the highest risk premium charged by a
carrier having an investment grade or better credit rating).  Notwithstanding the foregoing, the benefits
described in this Section 3(b)(viii) shall constitute secondary coverage with
respect to any health or life insurance benefits actually received by you in
connection with any subsequent employment (or self-employment) or otherwise
following your attainment of age 55.

(c) Excise Tax.  In the event you become entitled to any
amounts payable in connection with a Change in Control (whether or not such
amounts are payable pursuant to this Agreement) (the “Severance Payments”), if
any of such 

 5
 

Severance Payments are subject to the tax (the “Excise
Tax”) imposed by Section 4999 of the Code (or any similar federal, state or
local tax that may hereafter be imposed), the Company shall pay to you at the
time specified herein an additional amount (the “Gross-Up Payment”) such
that the net amount retained by you, after deduction of any Excise Tax on the
Total Payments (as hereinafter defined) and any federal, state and local income
tax and Excise Tax upon the payment provided for by this Section 3(c), shall be
equal to the Total Payments. For purposes of determining whether any of the
Severance Payments will be subject to the Excise Tax and the amount of such
Excise Tax: (i) any other payments or benefits received or to be received by
you in connection with a Change in Control or your termination of employment
(whether pursuant to the terms of this Agreement or any other plan, arrangement
or agreement with the Company, any Person whose actions result in a Change in
Control or any Person affiliated with the Company or such Person) (which,
together with the Severance Payments, constitute the “Total Payments”) shall be
treated as “parachute payments” within the meaning of Section 280G(b)(2) of the
Code, and all “excess parachute payments” within the meaning of Section
280G(b)(1) of the Code shall be treated as subject to the Excise Tax, unless in
the opinion of nationally-recognized tax counsel selected by you such other
payments or benefits (in whole or in part) do not constitute parachute
payments, or such excess parachute payments (in whole or in part) represent
reasonable compensation for services actually rendered within the meaning of
Section 280G(b)(4) of the Code in excess of the base amount within the meaning
of Section 280G(b)(3) of the Code, or are otherwise not subject to the Excise
Tax; (ii) the amount of the Total Payments which shall be treated as subject to
the Excise Tax shall be equal to the lesser of (A) the total amount of the
Total Payments and (B) the amount of excess parachute payments within the
meaning of Section 280G(b)(1) of the Code (after applying Section 3(c)(i)
hereof); and (iii) the value of any non-cash benefits or any deferred payments
or benefit shall be determined by a nationally-recognized accounting firm
selected by you in accordance with the principles of Sections 280G(d)(3) and
(4) of the Code.  For purposes of
determining the amount of the Gross-Up Payment, you shall be deemed to pay
federal income taxes at the highest marginal rate of federal income taxation in
the calendar year in which the Gross-Up Payment is to be made and state and
local income taxes at the highest marginal rate of taxation in the state and
locality of your residence on the Date of Termination, net of the maximum
reduction in federal income taxes which could be obtained from deduction of
such state and local taxes.  In the event
that the Excise Tax is subsequently determined to be less than the amount taken
into account hereunder at the time of termination of your employment, you shall
repay to the Company within ten days after the time that the amount of such
reduction in Excise Tax is finally determined the portion of the Gross-Up
Payment attributable to such reduction (plus the portion of the Gross-Up
Payment attributable to the Excise Tax and federal and state and local income
tax imposed on the Gross-Up Payment being repaid by you if such repayment
results in a reduction in Excise Tax and/or federal and state and local income
tax deduction) plus interest on the amount of such repayment at the rate
provided in Section 1274(b)(2)(B) of the Code. 
In the event that the Excise Tax is determined to exceed the amount
taken into account hereunder at the time of the termination of your employment
(including by reason of any payment the existence or amount of which cannot be
determined at the time of the Gross-Up Payment), the Company shall make an
additional gross-up payment in respect of such excess ten days after the time
that the amount of such excess is finally determined.  The payments provided for in this Section
3(c) shall be made on the fifteenth day following your Date of Termination; provided,
however, that if the amount of such payments cannot be finally determined
on or before such day, the Company shall pay you on such day an estimate, as
determined in good faith by the Company, of the minimum amount of such payments
and shall pay the remainder of such payments (together with interest at the
rate provided in Section 1274(b)(2)(B) of the Code) as soon as 

 6
 

administratively practicable in compliance with
Section 409A of the Code and the proposed and final Treasury Regulations
thereunder, as the same may be amended from time to time (the “Regulations”)
but in no event later than the thirtieth day after your Date of Termination
subject, however, to any delay in the payment date as a result of Section 3(d)
of this Agreement (relating to the six-month delay in payment of certain
benefits to Specified Employees as required by Section 409A of the Code).  In the event that the amount of the estimated
payments exceeds the amount subsequently determined to have been due, such
excess shall constitute a loan by the Company to you, payable on the fifteenth
day after the demand by the Company (together with interest at the rate provided
in Section 1274(b)(2)(B) of the Code).

(d) Delay in Payment
to Specified Employees.  Anything in
this Agreement to the contrary notwithstanding, payments to be made under this
Agreement upon your termination of employment which are subject to Section 409A
of the Code shall be delayed for six months following such termination of
employment if you are a “Specified Employee” as defined in Section 3(f) on your
Date of Termination.  Any payment due
within such six-month period shall be delayed to the end of such six-month
period. The Company will adjust the payment to reflect the deferred payment
date by multiplying the payment by the product of the six-month CMT Treasury
Bill annualized yield rate as published by the U.S. Treasury for the date on
which such payment would have been made but for the delay multiplied by a
fraction, the numerator of which is the number of days by which such payment
was delayed and the denominator of which is 365. The Company will pay the
adjusted payment at the beginning of the seventh month following your Date of
Termination. Notwithstanding the foregoing, if calculation of the amounts
payable by any payment date specified in this Section 3(d) is not
administratively practicable due to events beyond your control (or the control
of your beneficiary or estate) and for reasons that are commercially
reasonable, payment will be made as soon as administratively practicable in
compliance with Section 409A of the Code and the Regulations.  In the event of your death during such
six-month period, payment will be made in the payroll period next following the
payroll period in which your death occurs.

(e) Notice.  During the Protected Period, any purported
termination of your employment by the Company or by you shall be communicated
by written Notice of Termination to the other party hereto.

(f) Certain
Definitions.  Except as otherwise
indicated in this Agreement, all definitions in this Section 3(f) shall be
applicable during the Protected Period only.

(i) Cause.  “Cause” shall mean termination on account of
(A) the willful and continued failure by you to substantially perform your
duties with the Company (other than any such failure resulting from your
incapacity due to physical or mental illness or Disability or any failure after
the issuance of a Notice of Termination by you for Good Reason) which failure
is demonstrably and materially damaging to the financial condition or
reputation of the Company and/or its subsidiaries, and which failure continues
more than 48 hours after a written demand for substantial performance is
delivered to you by the Board, which demand specifically identifies the manner
in which the Board believes that you have not substantially performed your
duties and the demonstrable and material damage caused thereby or (B) the
willful engaging by you in conduct which is demonstrably and materially
injurious to the Company, monetarily or otherwise.  No act, or failure to act, on your part shall
be deemed “willful” unless done, or omitted to be done, by you not in good
faith and without reasonable belief that your action or omission was 

 7
 

in the best interest of the Company.  Notwithstanding the foregoing, you shall not
be deemed to have been terminated for Cause unless and until there shall have
been delivered to you a copy of the resolution duly adopted by the affirmative
vote of not less than three-quarters (3/4) of the entire membership of the
Board at a meeting of the Board (after reasonable notice to you and an
opportunity for you, together with your counsel, to be heard before the Board)
finding that, in the good faith opinion of the Board, you were guilty of
conduct set forth above in this Section 3(f)(i) and specifying the particulars
thereof in detail.

(ii) Date of
Termination.  “Date of Termination”
shall mean (A) if your employment is terminated for Disability, 30 days after
Notice of Termination is given (provided that you shall not have returned to
the full-time performance of your duties during such 30-day period) or (B) if
your employment is terminated for any other reason, the date specified in the
Notice of Termination (which, in the case of a termination for Cause, shall not
be less than 30 days from the date such Notice of Termination is given and, in
the case of a termination for Good Reason, shall not be less than 15 nor more
than 60 days from the date such Notice of Termination is given).

(iii) Disability.  “Disability” shall mean your absence from the
full-time performance of your duties with the Company for six consecutive
months as a result of your incapacity due to physical or mental illness or
disability, and within 30 days after written Notice of Termination is
thereafter given you shall not have returned to the full-time performance of
your duties.

(iv) Good Reason.  “Good Reason” shall mean, without your
express written consent, the occurrence upon or after a Change in Control of
any of the following circumstances unless, in the case of Sections 3(f)(iv)(A),
(D), (F) or (G) hereof, such circumstances are fully corrected prior to the
Date of Termination specified in the Notice of Termination given in respect
thereof:

(A) the assignment to you
of any duties inconsistent with the position in the Company that you held
immediately prior to the Change in Control, or an adverse alteration in the
nature or status of your responsibilities or the conditions of your employment
from those in effect immediately prior to such Change in Control;

(B) a reduction by the
Company in your annual base salary, any target bonus or perquisites as in
effect immediately prior to the Change in Control or as the same may be
increased from time to time except for across-the-board perquisite reductions
similarly affecting all senior executives of the Company and all senior
executives of any Person in control of the Company;

(C) the relocation of the
principle place of your employment to a location more than 50 miles from the
location of such place of employment on the date of this Agreement except for
required travel on the Company’s business to an extent substantially consistent
with your business travel obligations prior to the Change in Control;

(D) the failure by the
Company to pay to you any portion of your compensation or to pay to you any
portion of an installment of deferred compensation under any deferred
compensation program of the Company within seven days of the date such
compensation is due;

(E) the failure by the
Company to continue in effect any material compensation or benefit plan in
which you participated immediately prior to 

 8
 

the Change in Control, unless an equitable arrangement
(embodied in an ongoing substitute or alternative plan) has been made with
respect to such plan, or the failure by the Company to continue your
participation therein (or in such substitute or alternative plan) on a basis
not materially less favorable, both in terms of the amounts of benefits
provided and the level of your participation relative to other participants, as
existed at the time of the Change in Control;

(F) the failure of the
Company to obtain a satisfactory agreement from any successor to assume and
agree to perform this Agreement, as contemplated in Section 7 hereof; or

(G) any purported
termination of your employment that is not effected pursuant to a Notice of
Termination satisfying the requirements of Section 3(f)(v) (and, if applicable,
the requirements of Section 3(f)(i) hereof), which purported termination shall
not be effective for purposes of this Agreement.

(v) Notice of
Termination.  “Notice of Termination”
shall mean notice indicating the specific termination provision in this
Agreement relied upon and setting forth in reasonable detail the facts and
circumstances claimed to provide a basis for termination of your employment
under the provision so indicated.

(vi) Specified
Employee. “Specified Employee” shall mean an employee of the Company who
satisfies the requirements for being designated a “key employee” under Section
416(i)(1)(A)(i), (ii) or (iii) of the Code without regard to Section 416(i)(5)
of the Code at any time during a calendar year, in which case such employee shall
be considered a Specified Employee for the twelve-month period beginning on the
first day of the fourth month immediately following the end of such calendar
year. Notwithstanding the foregoing, all employees who are nonresident aliens
during an entire calendar year are excluded for purposes of determining which
employees meet the requirements of Section 416(i)(1)(A)(i), (ii) or (iii) of
the Code without regard to Section 416(i)(5) of the Code for such calendar
year. The term “nonresident alien” as used herein shall have the meaning set
forth in Regulations Section 1.409A-1(j). 
In the event of any corporate spinoff or merger, the determination of
which employees meet the requirements of Section 416(i)(1)(A)(i), (ii) or (iii)
of the Code without regard to Section 416(i)(5) of the Code for any calendar
year shall be determined in accordance with Regulations Section 1.409A-1(i)(2).

4. Mitigation.  Except as provided in Sections 3(b)(vii) and
(viii) and Section 6 hereof, you shall not be required to mitigate the amount
of any payment provided for under this Agreement by seeking other employment or
otherwise, nor shall the amount of any payment or benefit provided for under
this Agreement be reduced by any compensation earned by you as the result of
employment by another employer, by retirement benefits, by offset against any
amount claimed to be owed by you to the Company, or otherwise.

5.  Release of Employment Claims.  You agree, as a condition to your receipt of
the compensation and benefits provided for under this Agreement, that you will
execute a general release agreement, in substantially the form set forth as
Attachment A to this Agreement, releasing any and all claims arising out of
your employment other than: (a) the enforcement of this Agreement; (b) with
respect to vested rights or rights provided for under any benefit plan or
arrangement of the Company; or (c) rights to indemnification under any
agreement, law, Company organizational document or policy, or otherwise.

 9
 

6.  Forfeiture.  Except as otherwise provided in Section
3(b)(v) of this Agreement, if you willfully and materially fail to comply with
the terms of your Restrictive Covenant Agreement with the Company or if you
willfully and materially fail to comply with Section 2(c) or Section 5 of this
Agreement, all compensation and benefits provided for under this Agreement
shall be immediately forfeited. Notwithstanding the foregoing, you shall not
forfeit any compensation or benefits provided for under this Agreement unless
and until there shall have been delivered to you, within six months after the
Board (a) had knowledge of conduct or an event allegedly constituting grounds
for such forfeiture and (b) had reason to believe that such conduct or event
could be grounds for such forfeiture, a copy of a resolution duly adopted by a
majority affirmative vote of the membership of the Board at a meeting of the
Board called and held for such purpose (after giving you reasonable notice
specifying the nature of the grounds for such forfeiture and not less than 30
days to correct the acts or omissions complained of, if correctable, and
affording you the opportunity, together with your counsel, to be heard before
the Board) finding that, in the good faith opinion of the Board, you have
engaged and continue to engage in conduct which constitutes grounds for
forfeiture of your compensation and benefits under this Agreement; provided,
however, that in the event that you shall have already received any
compensation or benefits under this Agreement before the Board makes the
determination described in this sentence, you shall immediately reimburse the
Company for such compensation and/or benefits following such determination by
the Board. The forfeiture of any compensation or benefits provided for under
this Agreement by reason of this Section 6 shall apply to such compensation and
benefits notwithstanding any other term or provision of this Agreement or any
other agreement or plan.

7. Successors; Binding
Agreement.

(a) The Company shall
require any successor (whether direct or indirect, by purchase, merger,
consolidation or otherwise) to all or substantially all of the business and/or
assets of the Company to expressly assume and agree to perform this Agreement
in the same manner and to the same extent that the Company would be required to
perform it if no such succession had taken place.  As used in this Agreement, “Company” shall
mean the Company as hereinbefore defined and any successor to its business
and/or assets as aforesaid which assumes and agrees to perform this Agreement
by operation of law, or otherwise.

(b) This Agreement shall
inure to the benefit of and be enforceable by you and your personal or legal
representatives, executors, administrators, successors, heirs, distributees,
devisees and legatees.  In the event of
your death, all amounts otherwise payable to you hereunder shall, unless
otherwise provided herein, be paid in accordance with the terms of this
Agreement to your devisee, legatee or other designee or, if there is no such
designee, to your estate.

8. Notice.  Notices and all other communications provided
for in this Agreement shall be in writing and shall be deemed to have been duly
given when (a) personally delivered or (b) mailed by United States certified or
registered mail, return receipt requested, postage prepaid, addressed to the
respective addresses set forth on the first page of this Agreement; provided
that all notice to the Company shall be directed to the attention of the
Board with a copy to the General Counsel of the Company, or to such other
address as either party may have furnished to the other in writing in
accordance herewith, except that notice of change of address shall be effective
only upon receipt.

9. Miscellaneous.  No provision of this Agreement may be
modified, waived or discharged unless such waiver, modification or discharge is
agreed to in writing and 

 10
 

signed by you and such officer as may be designated by
the Board.  No waiver by either party
hereto at any time of any breach by the other party hereto of, or compliance
with, any condition or provision of this Agreement to be performed by such
other party shall be deemed a waiver of similar or dissimilar provisions or
conditions at the time or at any prior or subsequent time.  Any payments provided for hereunder shall be
paid net of any applicable withholding required under federal, state or local
law.  The obligations of the Company
under this Agreement shall survive the expiration of this Agreement to the
extent necessary to give effect to this Agreement.

10. Validity.  The invalidity or unenforceability of any
provision of this Agreement shall not affect the validity or enforceability of
any other provision of this Agreement, which shall remain in full force and
effect.

11. Counterparts.  This Agreement may be executed in
counterparts, each of which shall be deemed to be an original but all of which
together will constitute one and the same instrument.

12. Entire Agreement.  This Agreement sets forth the entire
agreement of the parties hereto in respect of the subject matter contained
herein and during the term of this Agreement supersedes the provisions of all
prior agreements, promises, covenants, arrangements, communications,
representations or warranties, whether oral or written, by any officer,
employee or representative of any party hereof with respect to the subject
matter contained herein.  No agreements
or representations, oral or otherwise, express or implied, with respect to the
subject matter hereof have been made by either party which are not expressly
set forth in this Agreement. 
Notwithstanding anything to the contrary in this Agreement, the
procedural provisions of this Agreement shall apply to all benefits payable as
a result of a Change in Control (or other change in control) under any employee
benefit plan, agreement, program, policy or arrangement of the Company.  The foregoing notwithstanding, in the event
of any conflict or ambiguity between this Agreement and any employment
agreement executed by you and the Company, the provisions of such employment agreement
shall govern; but no payment or benefit under this Agreement shall be made or
extended which duplicates any payment or benefit under any such employment
agreement.

13.  Governing Law.    This Agreement is
governed by and is to be construed, administered, and enforced in accordance
with the laws of the State of Connecticut, without regard to conflicts of law
principles. If under the governing law, any portion of this Agreement is at any
time deemed to be in conflict with any applicable statute, rule, regulation,
ordinance, or other principle of law, such portion shall be deemed to be
modified or altered to the extent necessary to conform thereto or, if that is
not possible, to be omitted from this Agreement. The invalidity of any such
portion shall not affect the force, effect, and validity of the remaining
portion hereof. Anything in this Agreement to the contrary notwithstanding, the
terms of this Agreement shall be interpreted and applied in a manner consistent
with the requirements of Section 409A of the Code and the Regulations
thereunder and the Company shall have no right to accelerate or make any
payment under this Agreement except to the extent permitted under Section 409A
of the Code.  The Company shall have no
obligation, however, to reimburse you for any tax penalty or interest payable
or provide a gross-up payment in connection with any tax liability you may
incur under Section 409A of the Code except that this provision shall not apply
in the event of the Company’s negligence or willful disregard in interpreting
the application of Section 409A of the Code to this Agreement which negligence
or willful disregard causes you to become subject to a tax penalty or interest
payable under Section 409A of the Code nor shall 

 11
 

this provision be interpreted to limit any gross-up
payable to you under Section 3(c) of this Agreement.

14.    Reimbursement of
Expenses in Enforcing Rights.    All
reasonable costs and expenses (including fees and disbursements of counsel)
incurred by you in seeking to interpret this Agreement or enforce rights
pursuant to this Agreement shall be paid on behalf of or reimbursed to you
promptly by the Company, whether or not you are successful in asserting such
rights; provided, however, that no reimbursement shall be made of such expenses
relating to any unsuccessful assertion of rights if and to the extent that your
assertion of such rights was in bad faith or frivolous, as determined by
arbitrators in accordance with Section 15 or a court having jurisdiction
over the matter.  Any such payment or
reimbursement shall be made in a lump sum in the month next following the month
in which such costs and expenses are incurred subject to your submission of
receipts for such expenses.

15.    Arbitration.    Any dispute or
controversy arising under or in connection with this Agreement shall be settled
exclusively by arbitration in Fairfield, Connecticut by three arbitrators in
accordance with the National Rules for the Resolution of Employment
Disputes of the American Arbitration Association in effect at the time of
submission to arbitration. Judgment may be entered on the arbitrators’ award in
any court having jurisdiction. For purposes of entering any judgment upon an
award rendered by the arbitrators, the Company and you hereby consent to the
jurisdiction of any or all of the following courts: (a) the United States
District Court for the District of Connecticut, (b) any of the courts of
the State of Connecticut, or (c) any other court having jurisdiction. The
Company and you further agree that any service of process or notice
requirements in any such proceeding shall be satisfied if the rules of
such court relating thereto have been substantially satisfied. The Company and
you hereby waive, to the fullest extent permitted by applicable law, any
objection which it may now or hereafter have to such jurisdiction and any
defense of inconvenient forum. The Company and you hereby agree that a judgment
upon an award rendered by the arbitrators may be enforced in other
jurisdictions by suit on the judgment or in any other manner provided by law.
Subject to Section 14, the Company shall bear all costs and expenses arising in
connection with any arbitration proceeding pursuant to this Section 15 and
shall pay such costs and expenses in the tax year in which incurred.
Notwithstanding any provision in this Section 15, you shall be paid during
the pendency of any dispute or controversy arising under or in connection with
this Agreement.

16.    Interest on Unpaid
Amounts.    Any
amount which has become payable pursuant to the terms of this Agreement or any
decision by arbitrators or judgment by a court of law pursuant to
Section 15 but which has not been timely paid shall bear interest at the
prime rate in effect at the time such amount first becomes payable, as quoted
by the Company’s principal bank, except as otherwise provided in Section 3(d)
of this Agreement (concerning interest payable with respect to delayed payments
under Section 409A of the Code).

 12
 

If this letter sets forth our agreement on the subject
matter hereof, kindly sign and return to the Company the enclosed copy of this
letter, which will then constitute our agreement on this subject.

	
  

  	
   

  	
  IMS HEALTH INCORPORATED

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  Chairman and Chief Executive Officer

  

 

	
  Agreed to this
                                         
  day

  	
   

  
	
   

  	
   

  
	
  of                                                       ,
  2007.

  	
   

  
	
   

  
	
   

  

 13
 

ATTACHMENT
A

RELEASE

We advise you to consult an attorney before you sign
this Release.  You have until the date
which is seven (7) days after the Release is signed and returned to IMS Health
Incorporated to change your mind and revoke your Release.  Your Release shall not become effective or
enforceable until after that date.

In consideration for the benefits provided under your
Change-in-Control Agreement with IMS Health Incorporated (the “Agreement”), by
your signature below, you, for yourself and on behalf of your heirs, executors,
agents, representatives, successors and assigns, hereby release and forever
discharge IMS Health Incorporated, its past and present parent corporations,
subsidiaries, divisions, subdivisions, affiliates and related companies
(collectively, the “Company”) and the Company’s past, present and future
agents, directors, officers, employees, representatives, assigns, stockholders,
attorneys, agents, insurers, employee benefit programs (and the trustees,
administrators, fiduciaries and insurers of such programs), and any other
persons acting by, through, under or in concert with any of the persons or
entities listed herein, and their successors (hereinafter “those associated
with the Company”) and with respect to any and all claims, demands, actions and
liabilities, whether in law or equity, which you may have against the Company
or those associated with the Company of whatever kind, including but not
limited to those arising out of your employment with the Company or the
termination of that employment.  You agree
that this Release covers, but is not limited to, claims arising under the Age
Discrimination in Employment Act of 1967, 29 U.S.C. § 621 et seq., Title VII of
the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., the Americans with
Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., the Fair Labor Standards
Act, 29 U.S.C. § 201 et seq., the Employee Retirement Income Security Act of
1974, 29 U.S.C. § 1001 et seq., the Family and Medical Leave Act of 1993 and
any local, state or federal law, regulation or order providing workers’
compensation benefits, restricting an employer’s right to terminate employees
or otherwise regulating employment, enforcing express or implied employment
contracts or requiring an employer to deal with employees fairly or in good
faith, or dealing with discrimination in employment on the basis of sex, race,
color, national origin, veteran status, marital status, religion, disability,
handicap, or age.  You also agree that
this Release includes claims based on wrongful termination of employment,
breach of contract (express or implied), tort, or claims otherwise related to
your employment or termination of employment with the Company and any claim for
attorneys’ fees, expenses or costs of litigation.

This Release covers all claims based on any facts or
events, whether known or unknown by you, that occurred on or before the date of
this Release. You expressly waive all rights you might have under any law that
is intended to protect you from waiving unknown claims and by your signature
below indicate your understanding of the significance of doing so. Examples of
released claims include, but are not limited to:  (a) claims that in any way relate to your
employment with the Company, or the termination of that employment, such as
claims for compensation, bonuses, commissions, lost wages, or unused accrued
vacation or sick pay (other than under your Agreement); (b) claims that in any
way relate to the design or administration of any employee benefit program; (c)
claims that you have irrevocable or vested rights to severance or similar
benefits (other than under your Agreement) or to post-employment health or
group insurance benefits (other than under your Agreement); (d) any claim, such
as a benefit claim, that was explicitly or implicitly denied before you signed
this Release; (e) any claim you might have for extra benefits as a consequence
of payments you receive because of signing this Release; or (f) any claim to
attorneys’ fees or other indemnities. 
Except to enforce your Agreement or this Release, you agree that you
will never commence, prosecute, or cause to be commenced or 

 14
 

prosecuted any lawsuit or proceeding of any kind
against the Company or those associated with the Company in any forum and agree
to withdraw with prejudice all complaints or charges, if any, that you have
filed against the Company or those associated with the Company.

Anything in this Release to the contrary
notwithstanding, this Release does not include a release of:  (i) any of your rights under the
Agreement;  (ii) any rights you may have
to indemnification under any agreement, law, Company organizational document or
policy, or otherwise; (iii) any rights you may have to benefits under the
Company’s benefit plans except as otherwise provided in your Agreement or
claims specifically identified in this Release; (iv) any rights or claims under
the Age Discrimination in Employment Act or any other law that arise after you
sign this Release; or (iii) your right to enforce this Release or any of the
foregoing items described in this paragraph.

By signing this Release, you further agree as follows:

i.              You
have read this Release carefully and fully understand its terms;

ii.             You
have had at least twenty-one (21) days to consider the terms of the Release;

iii.            You
have seven (7) days from the date you sign this Release to revoke it by written
notification to the Company.  After this
seven (7)-day period, this Release is final and binding and may not be revoked;

iv.            You
have been advised to seek legal counsel and have had an opportunity to do so;

v.             You
would not otherwise be entitled to the benefits provided under your Agreement
had you not agreed to execute this Release; and

vi.            Your
agreement to the terms set forth above is voluntary.

(The remainder of this page was intentionally left blank)

 15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]